{"text": "The primary goal of the study was to assess the incidence of infectious complications among this patient population .Moreno et al found that during the course of their HCV treatment , infectious complications were common : 84 patients , or 48 % of the population , experienced a total of 117 infections .", "label": "", "metadata": {}, "score": "34.173405"}
{"text": "HIV - infected patients were specifically excluded from this study .This was despite the finding that hyperlipidemia was marginally less common among HCV - infected patients than HCV - uninfected patients .", "label": "", "metadata": {}, "score": "35.020184"}
{"text": "30 % had no fibrosis , 40 % had portal fibrosis , 18 % had bridging fibrosis , and 8 % had cirrhosis .80 % of the patients were infected with HCV genotype 1 .", "label": "", "metadata": {}, "score": "36.591866"}
{"text": "Only 28.4 % of HIV / HCV - coinfected patients in the cohort had no contraindications to HCV treatment as per current treatment guidelines .( By comparison , 43.8 % of HCV - monoinfected patients had no contraindications to HCV treatment . )", "label": "", "metadata": {}, "score": "36.658123"}
{"text": "The truly alarming finding in our study , however , was that out of 20 HIV - infected patients with acute hepatitis C who underwent liver biopsy a median of four months after detection of the HCV , 17 had stage 2 ( out of 4 ) fibrosis .", "label": "", "metadata": {}, "score": "38.108612"}
{"text": "An FIB-4 index greater than 3.25 indicates advanced hepatic fibrosis .HIV / HCV status among participants was as follows : 1,410 HIV positive only , 296 HCV positive only , 701 HIV / HCV coinfected and 1,158 not infected with either HIV or HCV .", "label": "", "metadata": {}, "score": "38.18315"}
{"text": "In the Veterans Affairs HCV mono - infection population , SVR was associated with a marked reduction in all - cause mortality [ 16 ] ) .", "label": "", "metadata": {}, "score": "38.42374"}
{"text": "70 % of the patients were male , the mean age was 49 years , 70 % were Caucasian , and 89 % of the patients were infected with HCV genotype 1 .", "label": "", "metadata": {}, "score": "38.658714"}
{"text": "In our cohort of patients , we found a higher prevalence of advanced fibrosis ( F3-F4 ) in HCV-3 patients when compared to other genotypes .", "label": "", "metadata": {}, "score": "38.93871"}
{"text": "On the plus side , however , the researchers saw no significant opportunistic infections and no irreversible infections .Fifty - one of the patients , or 29 % , experienced grade 3 to 4 neutropenia , a complication that , if I saw it in one of my own patients , would cause me to become significantly concerned .", "label": "", "metadata": {}, "score": "40.661575"}
{"text": "Of 31 patients ( predominantly genotype 1 ) , 12 ( 38 % ) had an end of treatment response .Of those 12 , 11 had either completely non - detectable HCV RNA by 12 weeks or had at least a 2-log reduction in viral load .", "label": "", "metadata": {}, "score": "40.911575"}
{"text": "101 patients were enrolled in this study .All patients underwent a liver biopsy and an ultrasound to document the presence of HCV - related cirrhosis and the presence or absence of liver cancer .", "label": "", "metadata": {}, "score": "41.157806"}
{"text": "In this study only two patients ( 15 % ) in PNALT group showed significant inflammatory activity which may in part at least explain the slower liver fibrosis progression rate in these patients .", "label": "", "metadata": {}, "score": "41.225723"}
{"text": "The records of 3,327 HIV - infected patients were compared to those of 3,240 HIV - uninfected patients .As with most veterans ' studies , the population was almost entirely male .", "label": "", "metadata": {}, "score": "41.59813"}
{"text": "Other common reasons for not receiving HCV therapy included simply refusing treatment and being lost to follow - up .Interestingly , among patients with F2 or greater fibrosis , HIV - infected patients were much more likely to refuse treatment than their HIV - uninfected counterparts ( 57 % versus 27 % ) , but much less likely to be lost to follow - up ( 23 % versus 59 % ) .", "label": "", "metadata": {}, "score": "41.630173"}
{"text": "20 Twenty - nine patients with chronic HCV who then acquired HBV were compared to 29 patients who did not have chronic HCV and had acute HBV infection .", "label": "", "metadata": {}, "score": "42.12043"}
{"text": "The authors found important differences between the two ethnic groups .African Americans were more likely to be infected with HCV genotype 1 , to have lower ALT , and to have similar degrees of inflammation compared with Caucasians .", "label": "", "metadata": {}, "score": "42.271416"}
{"text": "Patients who achieved a virologic response had more pronounced decreases in HCV RNA levels after a single dose of IFN or during 14 days of daily IFN therapy .", "label": "", "metadata": {}, "score": "42.360085"}
{"text": "The median value for HCV viral load was high ( 6.3 log10 IU / mL ) , 98.8 % of the patients were infected with HCV genotype 1 .", "label": "", "metadata": {}, "score": "42.694485"}
{"text": "In conclusion , this study could demonstrate that HCV - HIV coinfected patients with persistently normal aminotransferases exposed to antiretroviral therapy would show mild histological lesions .", "label": "", "metadata": {}, "score": "43.088303"}
{"text": "Only two ( 15 % ) patients of group 1 had severe inflammatory activity .Furthermore , HCV - HIV co - infected patients with normal aminotransferases levels showed significantly lower liver fibrosis progression rates ( 0.058\u00b10.043 fibrosis unit ( FU)/year versus 0.118\u00b10.102 FU / year ) when compared to patients from group 2 ( Table 3 ) .", "label": "", "metadata": {}, "score": "43.218124"}
{"text": "In each alcohol use category , fibrosis was more prevalent among HIV- or HCV - positive patients compared to those not infected , with the highest incidence among participants coinfected with HIV and HCV .", "label": "", "metadata": {}, "score": "43.344086"}
{"text": "Steatosis .Steatosis was identified in 161 ( 48 % ) patients : 65 ( 40 % ) HCV-1 , 42 ( 26 % ) HCV-2 , 37 ( 23 % ) HCV-3 and 17 ( 11 % ) HCV-4 .", "label": "", "metadata": {}, "score": "44.228127"}
{"text": "Ninety percent of the patients in both groups were infected with HCV genotype 1 , and 38 % and 42 % of the patients in each group had stage 3 - 4 , respectively .", "label": "", "metadata": {}, "score": "44.500324"}
{"text": "This study evaluated these factors in 12 HCV+/HIV- hemophiliac subjects who were infected prior to 1987 and who cleared HCV spontaneously .The analysis was conducted using archived specimens that had been collected within 2 months to four year of primary HCV infection .", "label": "", "metadata": {}, "score": "44.74482"}
{"text": "During the larger trial , 64 of 4802 patients have had an infectious complication the most common of which were pneumonia , abscesses , cellulitis , and urinary tract infections .", "label": "", "metadata": {}, "score": "44.978706"}
{"text": "Perhaps even more importantly , there was no significant difference in the infection rate between patients whose CD4 + cell counts dropped below 200 cells / mm 3 and those whose CD4 + cell counts remained higher .", "label": "", "metadata": {}, "score": "44.986107"}
{"text": "Three out of 4 subjects with HCV RNA detectable by PCR on the first sample cleared virus during the next year .One patient was infected for five years before clearance , indicating that clearance can occur during chronic infection .", "label": "", "metadata": {}, "score": "45.047775"}
{"text": "Only patients with known HCV infection duration were selected .The HCV infection onset was considered as the first year of intravenous drugs usage , or transfusion .", "label": "", "metadata": {}, "score": "45.219727"}
{"text": "That was compared to 23 % of those who only had HCV .This was a predominantly male ( 75 % ) , majority African - American ( 63 % ) cohort .", "label": "", "metadata": {}, "score": "45.29236"}
{"text": "However , at multivariate analysis , AST values were independently associated with F3-F4 fibrosis , only ( Table 2 ) .Inflammation .In HCV-1 patients , univariate analysis identified older age and IL28B CC genotype as being associated to severe portal inflammation : both were confirmed by logistic regression analysis .", "label": "", "metadata": {}, "score": "46.143944"}
{"text": "Of this group , 93 of the patients ( 78 % ) were receiving antiretrovirals ; 60 % of study participants had an HIV viral load below 400 copies / mL at the time of their biopsy , and 48 % had a prior AIDS diagnosis .", "label": "", "metadata": {}, "score": "46.86155"}
{"text": "The researchers found that necroinflammation in patients who were not receiving antiretrovirals was much higher than in patients who were receiving antiretrovirals .Thirty patients ( 25 % ) had a necroinflammatory score of greater than or equal to 3 ( out of 4 ) .", "label": "", "metadata": {}, "score": "47.192307"}
{"text": "Those individuals with advanced fibrosis had a lower average neutrophil count than those with more modest forms of liver scarring .The authors concluded that the frequency of infectious complications did not differ significantly in patients based upon the average neutrophil count , the lowest neutrophil count , or number of new infections .", "label": "", "metadata": {}, "score": "47.262703"}
{"text": "They underwent liver ultrasonography and transient elastography .Results : No significant difference was found in steatosis - prevalence between mono- and co - infected patients ( 46.3 vs. 51.4 % ) .", "label": "", "metadata": {}, "score": "47.878895"}
{"text": "However , such an association was confirmed at multivariate analysis in HCV-1 patients only .Our findings , to some extent , corroborate a previous report of a correlation between histological features of liver inflammation and IL28B polymorphism in the overall HCV population [ 10 ] .", "label": "", "metadata": {}, "score": "47.885204"}
{"text": "Over a period of decades , about 50%- 60 % of chronically infected people develop a mild to moderate form of chronic liver disease that can result in fibrosis .", "label": "", "metadata": {}, "score": "47.969273"}
{"text": "About 15%-25 % of these individuals will die from complications of chronic liver disease .Hepatitis C Virus Infection .About 3.9 million Americans have been infected with HCV and 2.7 million have chronic HCV infection .", "label": "", "metadata": {}, "score": "47.970367"}
{"text": "15 That 's particularly important in this cohort , given that they almost uniformly have moderately advanced liver disease early in their infection ; 24 we have to be very concerned about an even more accelerated disease course in patients who are not cured of their HCV infection .", "label": "", "metadata": {}, "score": "48.10969"}
{"text": "This study evaluated the efficacy of daily interferon and ribavirin in U.S. Veterans .A total of 158 patients were enrolled in this study .At baseline , there were no significant differences in the percentage of patients with HCV genotype 1 , the stage of liver disease , or the number of African - American subjects in each group .", "label": "", "metadata": {}, "score": "48.15666"}
{"text": "An important part of the HIV - HCV co - infected patients had negative baseline predictors for the evolution of HCV infection ; their therapeutical management must be conducted with special attention towards adherence and potential overlapping drug toxicities .", "label": "", "metadata": {}, "score": "48.19505"}
{"text": "In this study , HCV RNA was below detection in 8 ( 57 % ) of the subjects by week 24 , 7 ( 50 % ) of the subjects by week 48 , and 6 ( 42 % ) of the subjects by week 72 .", "label": "", "metadata": {}, "score": "48.39814"}
{"text": "HCV infection in children is usually asymptomatic , is associated with normal ALT , and is associated with tremendous social stigma in younger age patients .", "label": "", "metadata": {}, "score": "48.963654"}
{"text": "This study is important because it focuses on a particular subgroup of HCV - infected patients , those who are inmates .A retrospective analysis of inmates with consecutive liver biopsies between October 1998 and July 2002 was conducted .", "label": "", "metadata": {}, "score": "48.976654"}
{"text": "All patients were HCV - treatment na\u00efve and had genotype 1 HCV infection .Non - nucleoside reverse - transcriptase inhibitors , zidovudine and didanosine were not permitted .", "label": "", "metadata": {}, "score": "49.17408"}
{"text": "However , he was never able to achieve an undetectable HCV viral load ; at 24 weeks , his reduction in HCV viral load had slowed , and was now at 3.42 log IU .", "label": "", "metadata": {}, "score": "49.223366"}
{"text": "Co- infected patients that had HIV RNA levels less than 1,000 copies / ML had a lower rate of hepatic decompensation than those with a lesser degree of HIV suppression .", "label": "", "metadata": {}, "score": "49.299698"}
{"text": "The average age at liver biopsy was 38\u00b16.6 years and 40 ( 80 % ) were males .The use of intravenous drugs was considered the virus acquisition mode in 43 ( 86 % ) patients .", "label": "", "metadata": {}, "score": "49.3973"}
{"text": "The meeting started with an interactive symposium .David Thomas , M.D. , M.P.H. , from Johns Hopkins University began his overview with a case presentation . 1 He presented the case of an HIV long - term nonprogressor who also had been infected with HCV for a number of years .", "label": "", "metadata": {}, "score": "49.520767"}
{"text": "Several studies have demonstrated the deleterious HIV immunodeficiency action on the natural history of chronic hepatitis C. The rate of liver fibrosis progression in HCV - HIV coinfected patients is about 1.5 to 2 times faster than in patients infected only by HCV 16 - 20 .", "label": "", "metadata": {}, "score": "49.57778"}
{"text": "However , the patient returned six or seven years later for a serologic test , the result of which suggested an F3 or F4 stage of fibrosis .", "label": "", "metadata": {}, "score": "49.63926"}
{"text": "RESULTS .Seventy - nine patients with positive antibody anti - HCV and HCV infection with known duration were selected .Three of these were excluded by presenting the HBsAg , four due to the absence of HCV - RNA , and 22 patients for loss of the pursuing or refusing the liver biopsy .", "label": "", "metadata": {}, "score": "49.755287"}
{"text": "In the Bani - Sadr study , none of the 36 patients with PNALT had cirrhosis 30 .In coinfected patients with normal aminotransferases levels Fonquernie et al demonstrated a significantly lower fibrosis score and fibrosis progression rate 29 .", "label": "", "metadata": {}, "score": "49.76303"}
{"text": "In our experience , those increases have been frequently attributed to their antiretroviral therapy , when in fact the patients turned out to have HCV infection .", "label": "", "metadata": {}, "score": "50.144173"}
{"text": "Aim : The study aims were to assess steatosis prevalence and its risk factors in both HCV groups .We also evaluated whether steatosis was linked with advanced fibrosis .", "label": "", "metadata": {}, "score": "50.2361"}
{"text": "The study enrolled participants in the Veterans Aging Cohort Study ( VACS ) at eight U.S. Department of Veterans Affairs ( VA ) facilities who reported alcohol use during the prior 12 months and had hepatic fibrosis data available .", "label": "", "metadata": {}, "score": "50.246628"}
{"text": "The authors concluded that the SVR for Veterans is approximately 10 % lower than it is for other HCV - infected patient groups .They also concluded that daily interferon is significantly better for genotype 1 infected patients than IFN three times per week , while the dosage frequency does not make a significant difference in the SVR for genotype 2 - 3 patients .", "label": "", "metadata": {}, "score": "50.298073"}
{"text": "All patients underwent biochemical and virological assessment , FIB4 score , HOMA and transient elastography .Seventy - five patients were evaluated .By ROC curve analysis the optimal cut - off for liver stiffness to identify high FIB4 was calculated as 10.1 kPa .", "label": "", "metadata": {}, "score": "50.60559"}
{"text": "About 80 % of people with HCV infection have no signs or symptoms when the infection first develops .Those who do have symptoms might experience : .", "label": "", "metadata": {}, "score": "50.646812"}
{"text": "The likelihood of treatment by degree of fibrosis was then examined .Reasonably , study patients with less fibrosis ( F0 or F1 ) were less likely to be treated for HCV ; 22 % of these patients received HCV therapy .", "label": "", "metadata": {}, "score": "50.73394"}
{"text": "Of the patients enrolled in the study , 43/71 of HCV RNA+ patients have had post treatment liver biopsies and 16/31 of the HCV RNA - have had post treatment liver biopsies .", "label": "", "metadata": {}, "score": "50.7874"}
{"text": "For the relatively small percentage of HIV / HCV - coinfected patients who do get treated for HCV , there were some interesting posters presented at ICAAC / IDSA 2008 regarding optimal strategies for HCV treatment .", "label": "", "metadata": {}, "score": "50.855835"}
{"text": "Eleven ( 18 % ) patients had Metavir F3 fibrosis and 16 ( 23 % ) had F4 fibrosis at inclusion into the study .A total of 39 % of patients were previous relapsers to dual therapy , 9 % had previous viral breakthrough , 22 % were partial responders and 30 % null - responders .", "label": "", "metadata": {}, "score": "50.89749"}
{"text": "55 patients who had never received treatment were enrolled and 48 completed therapy and follow - up .39 patients completed at least one set of depression scales .", "label": "", "metadata": {}, "score": "51.032608"}
{"text": "This was an almost entirely male cohort ; the mean age of the coinfected patients was 48.6 years , while the mean age of the monoinfected patients was 50.5 .", "label": "", "metadata": {}, "score": "51.21935"}
{"text": "Inmates with mild disease had lower ALT values and a high percentage had normal ALT .The authors concluded that there are no significant biochemical , clinical or histologic differences between African American and Caucasian HCV - infected inmates .", "label": "", "metadata": {}, "score": "51.368935"}
{"text": "About 1%-5 % of these individuals will die from complications of chronic liver disease .Most patients have no symptoms until the disease is far advanced .", "label": "", "metadata": {}, "score": "51.93355"}
{"text": "The authors concluded that HCV - specific Th1 responses in PBMCs correlate with milder inflammation and fibrosis on baseline liver histologic assessment .This is an important finding because it suggests that the stronger the immune response against the virus , the better the control of the virus , and the less liver injury will occur .", "label": "", "metadata": {}, "score": "52.11496"}
{"text": "This study evaluated 10 patients who were infected with HCV genotype 3a who were treated with PEG - IFN a2b 1.0 mcg / kg / qwk for four weeks .", "label": "", "metadata": {}, "score": "52.126404"}
{"text": "This study demonstrates that even patients who fail to have a viral response can have an improvement in liver histology .However , additional follow - up will be needed to determine if the improvement observed in inflammation will translate into improvements in fibrosis , particularly among those who are still HCV RNA positive .", "label": "", "metadata": {}, "score": "52.132233"}
{"text": "Fonquernie et al . reported among 155 HCV - HIV coinfected patients , 39 ( 28.5 % ) had persistently normal ALT levels 29 .In study involving 381 HCV - HIV coinfected patients , Bani - Sadr et al .", "label": "", "metadata": {}, "score": "52.306786"}
{"text": "However , despite attenuation of faster fibrosis progression with successful HAART , some patients continue to develop hepatocellular carcinoma and advanced liver disease .Therefore , the treatment of HCV is of the utmost clinical importance .", "label": "", "metadata": {}, "score": "52.322563"}
{"text": "In general , the SVR is decreased approximately 10 percent in co - infected patients treated with PEG - IFN / RBV compared with mono - infected patients treated with the same regimen .", "label": "", "metadata": {}, "score": "52.3347"}
{"text": "The good news was that in 10 of our patients who were treated during the acute phase , eight had a sustained virological response .This rate compares favorably to the overall 64 % that were reported from the general European cohort at the 2008 Conference on Retroviruses and Opportunistic Infections .", "label": "", "metadata": {}, "score": "52.369415"}
{"text": "Indeed , data from the EuroSIDA cohort suggest that not more than 25 % of all European HIV / HCV co - infected patients have ever received anti - HCV therapy [ 15 ] ) .", "label": "", "metadata": {}, "score": "52.531425"}
{"text": "Only a minority of patients ( 21 % ) who underwent a liver biopsy in other Centers ( but were enrolled in the MIST study once we could confirm their eligibility after reviewing their biopsy slides brought to consultation ) were excluded from this analysis .", "label": "", "metadata": {}, "score": "52.7092"}
{"text": "After all , an important observation about HCV disease progression in HIV / HCV - coinfected patients is that patients with AIDS or a very low CD4 + cell count appear to progress more quickly in their HCV disease than patients with much better - controlled HIV infection who are taking antiretroviral therapy .", "label": "", "metadata": {}, "score": "52.807106"}
{"text": "Interestingly , these observations mimic the findings by Rembeck et al . of a trend for higher rates of liver fibrosis in IL28B CC patients with HCV-3 infection with respect to similar patients carrying the T allele [ 15 ] .", "label": "", "metadata": {}, "score": "52.8724"}
{"text": "It is estimated that HCV seroprevalence is 0.2 - 0.4 % in children 12 - 18 years of age , which translates into 150,000 to 250,000 HCV - infected children in the United States .", "label": "", "metadata": {}, "score": "52.876404"}
{"text": "HCV RNA , PEG - IFN levels , and 2'5 ' OAS ( a measure of IFN activity ) were assessed at Day -7 , baseline , and at study weeks 1 , 2 , 3 , and 4 .", "label": "", "metadata": {}, "score": "52.8975"}
{"text": "The mode of HIV acquisition is directly associated with prevalence rates of HCV co - infection .Thus , the prevalence of HCV among men who have sex with men is approximately 10 % , while 70 - 90 % of the intravenous drugs users ( IDU ) are HCV co - infected 1,8,9 .", "label": "", "metadata": {}, "score": "53.227158"}
{"text": "In HCV - HIV coinfected Brazilian patients , the prevalence of individuals with normal aminotransferases levels , the rate of liver fibrosis progression and their histological characteristics , remain to be studied .", "label": "", "metadata": {}, "score": "53.50888"}
{"text": "It is limited because SVR data were not presented , only a small number of patients were evaluated , and the statistical methods that were used to analyze the data .", "label": "", "metadata": {}, "score": "53.561665"}
{"text": "8/12 ( 66 % ) of the patients did not have HCV RNA detected in the first sample .Eight of the twelve subjects had been infected by age 8.5 years .", "label": "", "metadata": {}, "score": "53.59185"}
{"text": "Two patients had on - treatment HCV breakthrough with telaprevir - resistant variants .Patients treated with antiretroviral drugs had no HIV breakthroughs ; antiretroviral exposure was not substantially modified by telaprevir .", "label": "", "metadata": {}, "score": "53.62516"}
{"text": "Higher rates of decompensation were seen in co - infected patients receiving ART who had baseline advanced liver fibrosis , severe anemia , diabetes , and were of nonblack race .", "label": "", "metadata": {}, "score": "53.643208"}
{"text": "The real effect of HAART on the natural history of chronic hepatitis C in HIV infected patients is still unclear .Two studies reported that HCV - HIV coinfected patients submitted to HAART based on the use of protease inhibitors presented slower liver fibrosis progression 21,22 .", "label": "", "metadata": {}, "score": "53.690662"}
{"text": "In addition , they have thus far only been tested to a significant extent in HIV - uninfected people , so we really do not know what the response will be in HIV / HCV - coinfected people .", "label": "", "metadata": {}, "score": "53.812717"}
{"text": "It is important to bear in mind that if this is the case , careful monitoring of fibrosis progression would be essential .Management of newly diagnosed HIV / HCV co - infected genotype 1 patients ( adapted with permission from [ 25 ] ) .", "label": "", "metadata": {}, "score": "53.97056"}
{"text": "HCV TREATMENT 213 .Clinical significance of pegylated interferon induced neutropenia ; Results from the WIN - R trial .In cancer patients , a low white blood cell count ( particularly of the neutrophil line ) can lead to an increased risk of infection .", "label": "", "metadata": {}, "score": "54.032112"}
{"text": "HCV PATHOPHYSIOLOGY 250 .Viral clearance occurs very early during the natural resolution of transfusion - acquired hepatitis C virus infection .The question of why some people are able to clear HCV while others go onto develop chronic infection has not yet been adequately answered .", "label": "", "metadata": {}, "score": "54.05642"}
{"text": "Individuals with chronic HBV and HCV infection should be under medical supervision .Antiviral Therapy Is Available for Chronic Hepatitis B and Chronic Hepatitis C .", "label": "", "metadata": {}, "score": "54.115177"}
{"text": "In chronic hepatitis C , the progression of liver fibrosis is slow , but steady .It has been reported that the progression rate of liver fibrosis is 0.10 - 0.13 U / year in untreated patients [ 8 ] .", "label": "", "metadata": {}, "score": "54.18353"}
{"text": "But what I do not believe has been described before was the possibility that having a high CD4 + cell count and being off antiretrovirals may lead to more rapid HCV progression .", "label": "", "metadata": {}, "score": "54.224804"}
{"text": "The researchers observed that HCV prevalence in their cohort was almost 71 % among those who entered the cohort in 1997 , but was only 16 % among those who entered in 2006 .", "label": "", "metadata": {}, "score": "54.336266"}
{"text": "A total of 18 % of patients developed anemia and 18 % a rash .Two rashes were documented as SAEs .The other second wave HCV protease inhibitor study evaluated efficacy and safety of simeprevir based triple therapy in HIV / HCV co - infection in study C212 .", "label": "", "metadata": {}, "score": "54.47471"}
{"text": "In some patients this was observed a year or two years after their initial diagnosis , suggesting that this was not a transient phenomenon : This fibrosis does persist .", "label": "", "metadata": {}, "score": "54.502556"}
{"text": "A large proportion of patients with HIV / HCV coinfection end up deciding against HCV treatment .To find out why most HIV / HCV - coinfected patients defer HCV treatment , and just how common an occurrence is this deferral , Adeel Butt , M.D. , et al conducted a systematic examination of HCV - infected individuals in U.S. Veterans Affairs National Patient Care Database .", "label": "", "metadata": {}, "score": "54.77319"}
{"text": "Patients with HBeAg - positive chronic hepatitis who have a substantial decrease in the level of HBV DNA and a loss of HBeAg at the end of therapy are considered to have had a virologic response to treatment .", "label": "", "metadata": {}, "score": "54.88526"}
{"text": "I encourage the authors to go back and analyze their data to look at HIV - infected patients with HCV as well ; this is a very powerful cohort that they can use to examine this subject .", "label": "", "metadata": {}, "score": "55.04484"}
{"text": "Introduction .Results .The HCV genotype distribution was 1 in 151 ( 45 % ) , 2 in 99 ( 30 % ) , 3 in 50 ( 15 % ) and 4 in 35 ( 10 % ) .", "label": "", "metadata": {}, "score": "55.288692"}
{"text": "BMJ 1996 ;313:461 - 464 .[Links ] .Mendel I , Clotteau L , Lambert S , Buffet - Janvresse C. Hepatitis C virus infection in HIV - positive population in Normandy : antibodies , HCV RNA and genotype prevalence .", "label": "", "metadata": {}, "score": "55.338043"}
{"text": "Consequently , the authors concluded that the 24-hour decline in HCV RNA levels after a single dose of IFN 10 MU has a high predictive value for subsequent outcome after treatment with combination therapy in patients infected with HCV genotype 4 .", "label": "", "metadata": {}, "score": "55.48638"}
{"text": "These investigators sought to test the hypothesis that vigorous HCV - specific T helper 1 interferon gamma responses are correlated with protection from liver damage in co - infected patients .", "label": "", "metadata": {}, "score": "55.660683"}
{"text": "Discussion .This notwithstanding , in HCV-1 patients portal inflammation was to some extent associated to host genetic background , as the IL28B genotype CC emerged as an independent predictor of severe portal inflammation together with advanced patient age .", "label": "", "metadata": {}, "score": "55.685722"}
{"text": "-F4 fibrosis was uniformly distributed among the cohort with respect to IL28B genotype ( CC vs. CT / TT : 41 % vs. 41 % ) .", "label": "", "metadata": {}, "score": "55.86396"}
{"text": "170 patients responded to therapy and 72 % had an early viral response .One of the limitations of this study concerns the manner in which the statistical modeling was performed .", "label": "", "metadata": {}, "score": "55.86715"}
{"text": "PubMed View Article .Pawlotsky JM : Treatment of chronic hepatitis C : current and future .Curr Top Microbiol Immunol 2013 , 369 : 321 - 342 .", "label": "", "metadata": {}, "score": "55.92702"}
{"text": "But these observations drive home the need for a large , randomized study to establish which antiretrovirals are the best choices for HIV / HCV - coinfected patients who are being concurrently treated for their chronic hepatitis C coinfection .", "label": "", "metadata": {}, "score": "56.063198"}
{"text": "167 patients were randomized to receive placebo and 171 were randomized to receive ADV for 48 weeks .At baseline , the two groups were fairly well matched in terms of the amount of scarring in the liver , the amount of HBV in the blood , and the ALT level in the blood .", "label": "", "metadata": {}, "score": "56.085426"}
{"text": "Ishak , K. ; Baptista , A. ; Bianchi , L. ; Callea , F. ; de Groote , J. ; Denk , F.G. ; Desmet , V. ; Korb , G. ; MacSween , R.N.M. Histological grading and staging of chronic hepatitis .", "label": "", "metadata": {}, "score": "56.248215"}
{"text": "Clin Infect Dis 2001 ; 32:492 - 497 .[Links ] .Cacoub P , Geffray L , Rosenthal E , Perronne C , Veyssier P , Raguin G. Mortality among human immunodeficiency virus - infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine / Infectious Diseases , in 1995 and 1997 .", "label": "", "metadata": {}, "score": "56.285816"}
{"text": "J Hepatol 2013 , 59 : 434 - 441 .PubMed View Article . 20thConference on Retroviruses and Opportunistic Infections , Atlanta 2013 . abstract 40LB .", "label": "", "metadata": {}, "score": "56.359406"}
{"text": "The authors concluded that clearance of HCV usually occurs in the first 1 - 2 years after infection and is more likely in those subjects with lower HCV RNA .", "label": "", "metadata": {}, "score": "56.391"}
{"text": "With easier to take , better tolerated and optimally interferon - free HCV treatment approaches on the horizon in the very near future , HCV treatment initiation can be delayed in all patients with low fibrosis stages .", "label": "", "metadata": {}, "score": "56.42065"}
{"text": "The most important finding of this study was that among HIV - infected patients with HCV coinfection , in a multivariate analysis , the risk of diabetes was increased by 36 % ; by comparison , among HIV - uninfected patients with HCV , the increased risk was 28 % .", "label": "", "metadata": {}, "score": "56.4802"}
{"text": "Nevertheless , numerous challenges remain , including choice of patients to treat , potential for drug - drug interactions and overlapping toxicities between HIV and HCV therapy .", "label": "", "metadata": {}, "score": "56.565212"}
{"text": "All patients were submitted to liver biopsy independent of ALT levels .Using METAVIR classification , a single experienced pathologist performed the histological evaluation .The fibrosis progression rate ( FPR ) was defined as the ratio between the fibrosis stage and HCV infection duration ( fibrosis units / year ) .", "label": "", "metadata": {}, "score": "56.60898"}
{"text": "PubMed .Lacombe K , Rockstroh J : HIV and viral hepatitis co - infections : advances and challenges .Gut 2012 , 61 : i47-i58 .", "label": "", "metadata": {}, "score": "56.65365"}
{"text": "However , my group at Mt. Sinai has been investigating an outbreak of HCV among MSM in Manhattan .23 Some of that work I presented at the ICAAC / IDSA 2008 meeting .", "label": "", "metadata": {}, "score": "56.804573"}
{"text": "Most people in the U.S. have genotype 1 infection .Genotypes 2 and 3 are more common in Europe .HCV infection differs from hepatitis A and hepatitis B virus infections in that only a relatively small percentage of the people who become infected with HCV clear the virus from their blood .", "label": "", "metadata": {}, "score": "56.914604"}
{"text": "Patients with more advanced liver fibrosis stages , however , are at risk of developing more severe liver disease associated complications and can be potentially cured now with the currently available DAA - based treatment regimens .", "label": "", "metadata": {}, "score": "56.94805"}
{"text": "This is a surprisingly severe outcome .However , something very interesting was observed on the other side of the equation : During the acute phase of HBV infection , all of the HCV - infected patients became HCV aviremic .", "label": "", "metadata": {}, "score": "56.959953"}
{"text": "The data presented above are important because they reinforce our clinical impression that HCV clearance occurs quickly after exposure to the infection .They also demonstrate that clearance after the onset of chronic infection is possible , implying that HCV RNA + patients who elect to defer treatment should be followed periodically to assess whether they clear the infection .", "label": "", "metadata": {}, "score": "57.291565"}
{"text": "Aims of this study were to analyse the association of two non - invasive liver fibrosis evaluation methods , liver stiffness measurement and FIB4 , and their correlation with metabolic parameters .", "label": "", "metadata": {}, "score": "57.410423"}
{"text": "They are chronically infected , which means that they carry the virus for the rest of their lives and can infect others .Over the course of several decades , about one - third of chronically infected people develop a mild to moderate form of chronic liver disease that can result in fibrosis ( scarring of liver tissue ) .", "label": "", "metadata": {}, "score": "57.476345"}
{"text": "RBV is currently prescribed according to either a fixed or a weight - based ( 13.6 mg / kg / d ) dosing scheme .--Duration and outcome of therapy : In HCV mono - infected patients , those infected with genotype 2 are usually treated for 24 weeks while those infected with genotype 1 are usually treated for 48 weeks .", "label": "", "metadata": {}, "score": "57.490894"}
{"text": "Those who were HCV RNA negative have had the most significant change in inflammation compared with those who were HCV RNA positive .The sustained virologic response among patients enrolled in this trial was 9 % , which is consistent with other trials of patients who failed to respond to interferon and ribavirin who were treated with pegylated interferon and ribavirin .", "label": "", "metadata": {}, "score": "57.508648"}
{"text": "No SAEs were reported .The most frequent AEs included fever ( 11 % ) and headache ( 6 % ) .Commentary : This study convincingly demonstrates that interferon monotherapy can be dosed effectively in children based upon BSA resulting in an SVR of 42 % .", "label": "", "metadata": {}, "score": "57.581528"}
{"text": "Hepatology 2013 , 58 , 1548 - 1557 .[ Google Scholar ] .D'Ambrosio , R. ; Aghemo , A. ; Rumi , M.G. ; Ronchi , G. ; Donato , M.F. ; Paradis , V. ; Colombo , M. ; Bedossa , P. A morphometrical and immunoistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis .", "label": "", "metadata": {}, "score": "57.598343"}
{"text": "During treatment , none of the patients withdrew secondary to depression .The use of medications to treat psychological problems increased from 26 % at baseline to 68 % during therapy .", "label": "", "metadata": {}, "score": "57.664223"}
{"text": "Commentary : Our impression has been that HCV infection is cleared very quickly .In the clinical setting , most practitioners have waited three to six months after the exposure prior to treating acute HCV in anticipation that a large number of subjects would clear the infection .", "label": "", "metadata": {}, "score": "57.70956"}
{"text": "41 patients were treated with IFN monotherapy 6 MU each day for 12 months and were followed for 5 years .Another sixty patients , thirty in each arm , were randomized to receive either no therapy or combination therapy with interferon and ribavirin .", "label": "", "metadata": {}, "score": "57.771156"}
{"text": "Practical recommendations : CD4-count level and drug - drug interactions .Cure rates of HCV therapy in HIV co - infection have been demonstrated to increase with higher CD4 relative percentage above 25 % , and undetectable HIV - RNA has been suggested to be independently associated with improved SVR rates ( [ 26 ] .", "label": "", "metadata": {}, "score": "57.78818"}
{"text": "At present , this therapy is difficult and is effective in less than half of people treated .Antiviral therapy may be appropriate for patients 18 years and older who : . have a liver biopsy showing either portal or bridging fibrosis or at least moderate degrees of inflammation and necrosis .", "label": "", "metadata": {}, "score": "57.816586"}
{"text": "A total of 64 % of all prior null responders had not experienced failure at the time of the interim analysis .Of the 88 % of patients who met RVR , 75 % achieved SVR 12 ; 30 % of patients developed grade 3 or 4 events .", "label": "", "metadata": {}, "score": "58.00756"}
{"text": "Among treatment - experienced patients with advanced fibrosis or cirrhosis , previous relapsers are likely to respond very well to telaprevir- or boceprevir - based treatment , although advanced liver disease had a greater influence on SVR rates in previous nonresponders [ 39 , 42 , 62 , 63 ] .", "label": "", "metadata": {}, "score": "58.103325"}
{"text": "Ann Intern Med 2002 ; 137:1 - 10 .[Links ] .Strader DB , Wright T , Thomas DL , Seeff LB .Diagnosis , management , and treatment of hepatitis C. Hepatology 2004 ; 39:1147 - 1171 .", "label": "", "metadata": {}, "score": "58.15867"}
{"text": "Advanced fibrosis was n't significantly associated with steatosis .The area under the ROC curve was 0.85 ( 95 % CI 0.79 - 0.9 ) .", "label": "", "metadata": {}, "score": "58.18059"}
{"text": "Besides the fibrosis stage , previous response to interferon- and ribavirin - based dual HCV therapy is also important information in the decision making process .", "label": "", "metadata": {}, "score": "58.229126"}
{"text": "( As far as we have seen , and as the study I reviewed earlier suggests , 11 interrupting treatment has been associated with worse HCV outcomes . )", "label": "", "metadata": {}, "score": "58.303776"}
{"text": "One half of the participants also had significant psychiatric conditions .The authors noted that there was an increase in methadone levels in 64 % of the participants ( by 10 - 15 % ) from week 0 - 4 .", "label": "", "metadata": {}, "score": "58.358658"}
{"text": "[Links ] .Ockenga J , Tillmann HL , Trautwein C , Stoll M , Manns MP , Schmidt RE .Hepatitis B and C in HIV - infected patients .", "label": "", "metadata": {}, "score": "58.387466"}
{"text": "Other outcomes that were evaluated in this study included the median change in HBV DNA- 3 log10 ( i.e. decreasing from 1,000,000 to 1,000 ) among the patients who received ADV compared with a less than 1 log10 among the patients who received placebo .", "label": "", "metadata": {}, "score": "58.838608"}
{"text": "After 24 weeks of treatment , most of the subjects ' psychiatric conditions continued and had not returned to baseline .One of the potential limitations of this study is how generalizable are the results .", "label": "", "metadata": {}, "score": "59.0272"}
{"text": "In terms of fibrosis progression , 6 % of those who received ADV compared with 13 % of those patients who received placebo progressed from F0/F2 to F3/F4 during the 48 weeks of the study .", "label": "", "metadata": {}, "score": "59.075333"}
{"text": "Adeyemi OM , Attar B , Huhn G , Wolen D , Gallagher M , Goldberg R. Low HCV treatment rates after a liver biopsy .", "label": "", "metadata": {}, "score": "59.119865"}
{"text": "Steatosis influences the early virologic response rate in patients with chronic hepatitis C infection .Current therapy for HCV is unsatisfactory on many levels : approximately one half of the patients who take it will fail to respond , the treatment is associated with significant side effects , and it is not suitable for all patients .", "label": "", "metadata": {}, "score": "59.12426"}
{"text": "It has been demonstrated that subjects who achieve sustained virological response ( SVR ) have a clear advantage at histological and clinical levels compared to those who do not achieve SVR [ 8 - 12 ] .", "label": "", "metadata": {}, "score": "59.285393"}
{"text": "In hopes of addressing this question , Ana Moreno and colleagues from Hospital Ram\u00f3n y Cajal in Madrid , Spain , conducted a prospective , nonrandomized study of 174 HIV / HCV - coinfected patients who initiated therapy for chronic HCV between January 2001 and March 2006 .", "label": "", "metadata": {}, "score": "59.313705"}
{"text": "A group of patients were used as controls who were HIV RNA + and HCV RNA - .The Knodell histologic activity index ( HAI ) was used blindly to assess the liver biopsy and advanced fibrosis was defined as bridging fibrosis or cirrhosis .", "label": "", "metadata": {}, "score": "59.35901"}
{"text": "Analyses of all patients from the different treatment arms showed that SVR occurred in 74 % ( 28 in 38 ) of patients receiving telaprevir plus PEG - IFN - \u03b12a / RBV and 45 % ( 10 in 22 ) of patients receiving placebo plus PEG - IFN - \u03b1-2a / RBV .", "label": "", "metadata": {}, "score": "59.501556"}
{"text": "After a total of 12 weeks , patients in the placebo group who had hemoglobin below 12 gm / dL were crossed over and were treated with rHuEPO .", "label": "", "metadata": {}, "score": "59.55366"}
{"text": "Recently , two pilot studies , one with boceprevir- and one with telaprevir - based HCV therapy , have been published with full SVR24 results in treatment - na\u00efve HIV / HCV co - infected patients and are briefly summarized below [ 10 , 11 ] .", "label": "", "metadata": {}, "score": "59.603233"}
{"text": "In summary , ICAAC / IDSA 2008 continues the theme set at previous conferences , which is that there is still no home - run treatment for HCV in our HIV / HCV - coinfected patients that will be available in the near future .", "label": "", "metadata": {}, "score": "59.643906"}
{"text": "Calculations were done with Stata 10.0 statistical package .Conclusions .IL28B genotype is associated with the histological features of chronic hepatitis C in a HCV genotype dependent manner , with CC genotype being independently associated with severe portal inflammation .", "label": "", "metadata": {}, "score": "59.648743"}
{"text": "This strategy offers the advantage of decreased pill burden , lack of overlapping toxicities between HIV and HCV drugs and no drug - drug interactions .", "label": "", "metadata": {}, "score": "59.688923"}
{"text": "Links ] .Zeuzem S , Alberti A , Rosenberg W , Marcellin P , Diago M , Negro F , et al .Review article : management of patients with chronic hepatitis C virus infection and \" normal \" alanine aminotransferase activity .", "label": "", "metadata": {}, "score": "59.811455"}
{"text": "Preventive measures against HCV , including vaccine development , are now in progress [ 13 ] .Rash also occurs in 56 % of patients treated with NSOC , compared to 34 % of patients treated with SOC alone .", "label": "", "metadata": {}, "score": "59.821865"}
{"text": "There was only 1 biopsy .This limitation prevents you from evaluating change in the liver over time .This limitation prevents you from considering ARV prior to current regimens as prior ARV experience probably differed between patients .", "label": "", "metadata": {}, "score": "59.83584"}
{"text": "In the natural course of hepatitis C in HIV , in the absence of antiretroviral therapy , a faster progression of hepatic fibrosis has been observed .", "label": "", "metadata": {}, "score": "59.857113"}
{"text": "There are also several noninvasive markers that are being evaluated in prospective studies that may permit us to assess the stage of fibrosis without the need for a liver biopsy .", "label": "", "metadata": {}, "score": "59.887276"}
{"text": "The primary endpoint of the study was at least a two - point improvement in the amount of scarring in the liver at 48 weeks .", "label": "", "metadata": {}, "score": "59.906734"}
{"text": "J Infect Dis 2008 , 198 : 1337 - 1344 .PubMed View Article .Rockstroh JK , Spengler U , Sudhop T , Ewig S , Theisen A , Hammerstein U , Bierhoff E , Fischer HP , Oldenburg J , Brackmann HH , Sauerbruch T : Immunosuppression may lead to progression of hepatitis C virus - associated liver disease in hemophiliacs coinfected with HIV .", "label": "", "metadata": {}, "score": "59.979015"}
{"text": "As the HIV treatment pendulum swings toward earlier ART ( antiretroviral therapy ) initiation , 9 we increasingly face the question regarding how to manage HIV treatment in our HIV / HCV - coinfected patients .", "label": "", "metadata": {}, "score": "60.03921"}
{"text": "The aim of this study was to assess the impact of HIV protease inhibitors on the spectrum of liver disease in HIV / HCV co - infected patients .", "label": "", "metadata": {}, "score": "60.04704"}
{"text": "Sanchez - Conde et al . reported 24/256 ( 9.4 % ) HIV - HCV coinfected patients with persistently normal ALT levels 31 .In the present study , we found 13/50 ( 26 % ) coinfected patients on HAART with persistently normal aminotransferases levels .", "label": "", "metadata": {}, "score": "60.103508"}
{"text": "Genotype 1 is more common in this country , but is not as responsive to therapy as genotypes 2 or 3 .HCV TREATMENT IN SELECTED PATIENT SUBGROUPS 217 .", "label": "", "metadata": {}, "score": "60.114902"}
{"text": "[Links ] .Shiffman ML , Diago M , Tran A , Pockros P , Reindollar R , Prati D , et al .Chronic hepatitis C in patients with persistently normal alanine transaminase levels .", "label": "", "metadata": {}, "score": "60.171406"}
{"text": "These patients should be managed withincenters with experience in looking after co - infected patients with advanced liver disease .Trial results with new DAAs in HIV / HCV co - infected individuals .", "label": "", "metadata": {}, "score": "60.27692"}
{"text": "Several studies have demonstrated that there are important differences in liver inflammation and response to therapy between African Americans and Caucasians in the general population .", "label": "", "metadata": {}, "score": "60.338326"}
{"text": "More intriguing was the initial finding of a protective - like effect of IL28B CC genotype on the prevalence of histological steatosis in patients with chronic HCV-1 infection , which after adjustment for the other clinical features , was not confirmed by multivariate analysis .", "label": "", "metadata": {}, "score": "60.338554"}
{"text": "Subsequently between day 0 and 14 , patients received IFN 5 MU per day .All patients received RBV 1 or 1.2 gm / day .", "label": "", "metadata": {}, "score": "60.3416"}
{"text": "There were no significant differences in SVR rates between the groups ( A : 6 % vs. B : 10 % ) .There were no significant differences in the number of adverse events or the number of patients who had to have the dose of the medication reduced between the two groups .", "label": "", "metadata": {}, "score": "60.376396"}
{"text": "To date , the results of the studies suggest excellent treatment response rates with SVRs in the range of 60 to 80 % and an increase in SVRs by 29 to 35 % when pegIFN and RBV were used as comparators [ 10 - 13 ] .", "label": "", "metadata": {}, "score": "60.40009"}
{"text": "In terms of changes in HCV RNA measurements , there were no significant differences reported in the two groups .The authors concluded that rHuEPO in anemic patients who are taking RBV can : 1 ) enable the patients to maintain full - dose RBV , and 2 ) result in a significant increase in hemoglobin and quality of life .", "label": "", "metadata": {}, "score": "60.41102"}
{"text": "11 Some of the diseases make treatment very risky , for instance decompensated liver cirrhosis and perhaps severe lung disease .This list of contraindications , however , may have become something of a wastebasket over time , since it also includes such things as anemia and substance abuse , which unless incapacitating , most experienced HCV - treaters do not consider significant barriers to treatment .", "label": "", "metadata": {}, "score": "60.504826"}
{"text": "RESULTS : Of 50 studied patients 40 ( 80 % ) were males .All patients were treated with antiretroviral therapy .The ALT levels were normal in 13 ( 26 % ) patients .", "label": "", "metadata": {}, "score": "60.656242"}
{"text": "Individuals with chronic HBV infection -- those who have tested positive for hepatitis B surface antigen ( HBsAg ) for at least 6 months -- should have an initial evaluation that consists of : .", "label": "", "metadata": {}, "score": "60.741295"}
{"text": "14 Both arms also received 180 \u00b5g per week of peginterferon alfa-2a and , in hopes of curbing the incidence of anemia , a pre - emptive dose of erythropoietin at 30,000 IU per week during the first four weeks of HCV therapy .", "label": "", "metadata": {}, "score": "60.868717"}
{"text": "[Links ] .Quaranta JF , Delaney SR , Alleman S , Cassuto JP , Dellamonica P , Allain JP .Prevalence of antibody to hepatitis C virus ( HCV ) in HIV-1-infected patients .", "label": "", "metadata": {}, "score": "60.91219"}
{"text": "[Links ] .Staples Jr CT , Rimland D , Dudas D. Hepatitis C in the HIV ( human immunodeficiency virus ) Atlanta V.A. ( Veterans Affairs Medical Center ) Cohort Study ( HAVACS ) : the effect of coinfection on survival .", "label": "", "metadata": {}, "score": "60.973907"}
{"text": "22 Some of those reports suggest an incidence rate that actually approached that seen in earlier years during which time injection drug use was the primary mode of HCV transmission .", "label": "", "metadata": {}, "score": "61.043613"}
{"text": "T1208 .Non - invasive assessment of fibrosis resolution / progressive in chronic hepatitis C patients who received anti - viral therapy .The main way that hepatitis C virus causes damage to the body is by causing liver fibrosis .", "label": "", "metadata": {}, "score": "61.101234"}
{"text": "Combination HCV therapy with simeprevir 150 mg q.d .+ pegIFN / RBV led to high virologic response rates in co - infected patients , regardless of prior response ( SVR12 77 % in treatment - na\u00efve and prior relapsers ) .", "label": "", "metadata": {}, "score": "61.111664"}
{"text": "Overall , 17 % of patients had Metavir F4 fibrosis at baseline and 33 % were previous null - responders .Overall , 63 % achieved undetectability at Week 16 , which was slightly higher in the RAL - treated patients than in patients on other ART regimens .", "label": "", "metadata": {}, "score": "61.154915"}
{"text": "Am J Gastroenterol 2002 ; 97:2071 - 2078 .[Links ] .Sherman KE , Rouster SD , Chung RT , Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus : a cross - sectional analysis of the US adult AIDS Clinical Trials Group .", "label": "", "metadata": {}, "score": "61.197872"}
{"text": "In his symposium at ICAAC / IDSA 2008 , Dr. Sulkowski emphasized that our 2008 goal for HCV treatment is viral eradication . 15( This goal is clearly not as realistic as our 2008 goal for HIV therapy , which is to help everyone on HIV treatment attain an undetectable viral load and which we need to aspire to with HCV as well . )", "label": "", "metadata": {}, "score": "61.206234"}
{"text": "At ICAAC / IDSA 2008 , Santiago Moreno , of the Hospital Ram\u00f3n y Cajal in Madrid , Spain , and colleagues looked at two Spanish cohorts to establish the prevalence of HCV over time .", "label": "", "metadata": {}, "score": "61.220142"}
{"text": "Although they offered few specific treatment remedies , we can see that for our HIV / HCV - coinfected patients enhanced surveillance might be the most effective tool , since they already appear to have lower lipid levels than HCV - monoinfected patients .", "label": "", "metadata": {}, "score": "61.286354"}
{"text": "Rodriguez - Torres M , Slim J , Bhatti L , Sterling R , Sulkowski M , Hassanein T , Serr\u00e3o R , Sola R , Bertasso A , Passe And S , Stancic S : Peginterferon alfa-2a plus ribavirin for HIV - HCV genotype 1 coinfected patients : a randomized international trial .", "label": "", "metadata": {}, "score": "61.46427"}
{"text": "HCV drugs in the future .New drugs for the treatment of hepatitis C are now being investigated in phase II and phase III clinical trials ( Tables 5 and 6 ) .", "label": "", "metadata": {}, "score": "61.47187"}
{"text": "PubMed View Article .J Acquir Immune Defic Syndr 2008 , 47 : 36 - 49 .PubMed View Article .Rodriguez - Torres M , Gonzalez M , Rossi S , et al .", "label": "", "metadata": {}, "score": "61.48325"}
{"text": "[Links ] .Antonello VS , Tovo CV , Kliemann DA , Santos BR , Zaltron VF .Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients .", "label": "", "metadata": {}, "score": "61.524277"}
{"text": "In the Sanchez - Conde study , patients infected with HCV genotype 3 were significantly more common between patients with altered ALT levels than in patients with persistently normal ALT levels 31 .", "label": "", "metadata": {}, "score": "61.69587"}
{"text": "Bedossa , P. ; Poynard , T. An alghoritm for the grading of activity in chronic hepatitis C. Hepatology 1996 , 24 , 289 - 293 .", "label": "", "metadata": {}, "score": "61.812378"}
{"text": "Keywords : .Review .Introduction .Hepatitis C virus ( HCV ) chronically infects an estimated 170 million people worldwide [ 1 ] .HCV infection is one of the major causes of end - stage liver disease and hepatocellular carcinoma ( HCC ) worldwide [ 2 - 4 ] .", "label": "", "metadata": {}, "score": "61.855057"}
{"text": "found that HAART reduced liver related mortality in HCV - HIV coinfected patients 23 .Approximately 30 % of chronic hepatitis C carriers present persistently normal alanine aminotransferase ( ALT ) levels .", "label": "", "metadata": {}, "score": "61.918346"}
{"text": "At Week 24 , ETS were re - randomized to stop treatment at Week 24 or continue pegIFN / RBV through Week 48 .Patients without ETS received pegIFN / RBV through Week 48 .", "label": "", "metadata": {}, "score": "62.176796"}
{"text": "[Links ] .Persico M , Perrotta S , Persico E , Terracciano L , Folgori A , Ruggeri L , et al .Hepatitis C virus carriers with persistently normal ALT levels : biological peculiarities and update of the natural history of liver disease at 10 years .", "label": "", "metadata": {}, "score": "62.22489"}
{"text": "All things considered , I think that this study is reassuring .Although it 's not clear that we really need to use G - CSF in patients who have significant neutropenia , it is comforting to see evidence that we are not likely to induce opportunistic infections with HCV therapy .", "label": "", "metadata": {}, "score": "62.3249"}
{"text": "Gastroenterology 2010 , 139 , 821 - 827 .[ Google Scholar ] .De Nicola , S. ; Aghemo , A. ; Rumi , M.G. ; Galmozzi , E. ; Valenti , L. ; Soffredini , R. ; de Francesco , R. ; Prati , G.M. ; D'Ambrosio , R. ; Cheroniet , C. ; et al .", "label": "", "metadata": {}, "score": "62.36419"}
{"text": "The goal of this study was to assess whether measurement of certain substances that are products of liver fibrosis in the peripheral blood could provide an accurate indication whether fibrosis was improving in patients who were on therapy .", "label": "", "metadata": {}, "score": "62.37877"}
{"text": "Prospective studies and outcome modeling projections suggest that the risk of liver disease progression towards severe fibrosis / cirrhosis is minimal at 10 - 15 years in hepatitis C virus carriers with persistently normal ALT 28 .", "label": "", "metadata": {}, "score": "62.46879"}
{"text": "A cohort of eight controls of similar age , gender , and duration of exposure to blood products ( which is important since the blood products serve as the primary route of infection ) as the hemophiliac cases was selected for comparison .", "label": "", "metadata": {}, "score": "62.505184"}
{"text": "IL28B genotype was CC in 117 ( 35 % ) and CT / TT in 218 ( 65 % )( Table 1 ) .The median length of liver cores was 21 ( 12 - 54 ) mm ; all LB were considered adequate for histological evaluation .", "label": "", "metadata": {}, "score": "62.57583"}
{"text": "While a number of new DAA - based therapies and IFN - free therapies , including combinations within fixed - drug combination tablets are in phase 2 and phase 3 clinical trials for mono - infected patients , there are an increasing number of studies underway or in the planning stage for co - infected patients .", "label": "", "metadata": {}, "score": "62.71524"}
{"text": "The Multivirc Group : Hepatology 1999 ; 30:1054 - 1058 .[Links ] .Soto B , Sanchez - Quijano A , Rodrigo L , del Olmo JA , Garcia - Bengoechea M , Hernandez - Quero J , et al .", "label": "", "metadata": {}, "score": "62.7719"}
{"text": "McHutchison JG , Everson GT , Gordon SC , Jacobson IM , Sulkowski M , Kauffman R , McNair L , Alam J , Muir AJ , PROVE1 Study Team : Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "62.928947"}
{"text": "Hepatitis B Virus Infection .About 5 % of Americans have been infected with HBV and 1.25 million have chronic HBV infection .In 2000 , about 73,000 people in the United States were newly infected with HBV .", "label": "", "metadata": {}, "score": "63.02455"}
{"text": "Gastroenterology 2010 , 138 , 1338 - 1345 .[ Google Scholar ] .Ge , D. ; fellay , J. ; Thompson , A.J. ; Simon , J.S. ; Shianna , K.V. ; Urban , T.J. ; Heinzen , E.L. ; Qiu , P. ; Bertelsen , A.H. ; Muir , A.J. ; et al .", "label": "", "metadata": {}, "score": "63.03759"}
{"text": "Table 4 .New standard of care treatment with other drugs ( second - generation DAAs ) chronic hepatitis C patients .MK-5172 , a novel P2-P4 quinoxaline macrocyclic peptide , maintained potency across a genetically diverse panel of genotype 1a and 1b sequences from plasma of HCV - infected patients .", "label": "", "metadata": {}, "score": "63.049812"}
{"text": "Responses to candida and PHA ( positive control ) were also assessed .The mean CD4 cell count was 479 cells / mm3 , 83 % of the subjects were male , 79 % of the subjects were infected with genotype 1 , and 88 % were taking antiretroviral therapy .", "label": "", "metadata": {}, "score": "63.078735"}
{"text": "Patients who have a sustained loss of HBsAg are deemed to have a complete response to antiviral therapy , but this does not happen very often .", "label": "", "metadata": {}, "score": "63.167824"}
{"text": "[Links ] .Alberti A , Noventa F , Benvegnu L , Boccato S , Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection .", "label": "", "metadata": {}, "score": "63.273647"}
{"text": "PubMed View Article . 20thConference on Retroviruses and Opportunistic Infections , Atlanta 2013 . abstract 154LB .Ingiliz P , Rockstroh JK : HIV - HCV co - infection facing HCV protease inhibitor licensing : implications for clinicians .", "label": "", "metadata": {}, "score": "63.38182"}
{"text": "The cluster of differentiation ( CD4 ) cell count was above 200 cells / mm 3 in 84 % of patients and the HIV viral load was less than 400 copies / mm 3 in 48 % of the sample ( Table 2 ) .", "label": "", "metadata": {}, "score": "63.46022"}
{"text": "The association of hepatitis C virus ( HCV)-specific immune responses with liver histology in subjects with HIV / HCV co - infection .HCV PATHOPHYSIOLOGY --Viral clearance occurs very early during the natural resolution of transfusion - acquired hepatitis C virus infection .", "label": "", "metadata": {}, "score": "63.464424"}
{"text": "Therefore , for HIV patients with genotype 2,3 and 4 where no licensed DAAs are currently available , dual HCV therapy with pegIFN and RBV remains the gold standard .", "label": "", "metadata": {}, "score": "63.48236"}
{"text": "Unfortunately , that study focusing on HCV-1 patients only missed any correlation analysis with the Ishak classification .The correlation between Il28B and liver inflammation was the focus of another study in a cohort of untreated patients with HCV-2 and HCV-3 patients which revealed a significant association between IL28B CC genotype and portal inflammation in HCV-3 patients but not in HCV-2 patients [ 15 ] .", "label": "", "metadata": {}, "score": "63.52381"}
{"text": "[Links ] .Alberti A , Benvegnu L , Boccato S , Ferrari A , Sebastiani G. Natural history of initially mild chronic hepatitis C. Dig Liver Dis 2004 ; 36:646 - 654 .", "label": "", "metadata": {}, "score": "63.594406"}
{"text": "It has become standard clinical practice that HCV monoinfected patients who do not have at least a two log10 reduction in HCV RNA by week 12 should not be continued on PEG - IFN alfa / RBV .", "label": "", "metadata": {}, "score": "63.64385"}
{"text": "To answer this question , the authors reviewed the medical records of consecutive patients ( retrospective analysis ) who were seen in the Liver Clinic at Virginia Medical College in Richmond between 1997 - 2002 .", "label": "", "metadata": {}, "score": "63.65954"}
{"text": "A very large study was presented by Adeel Butt , M.D. 18 ( who also presented a study mentioned earlier detailing reasons for HCV therapy deferral 12 ) .", "label": "", "metadata": {}, "score": "63.734436"}
{"text": "There was an interesting Spanish study presented at ICAAC / IDSA 2008 that addressed this issue by focusing on the incidence of hepatic necroinflammatory activity in patients with a high CD4 + cell count .", "label": "", "metadata": {}, "score": "63.740807"}
{"text": "The study authors suggest the following clinical implications for HIV care practitioners : .Use the AUDIT - C questionnaire during routine care and explain the potential effects of the patient 's alcohol use category on the liver in order to motivate the patient to reduce his or her alcohol consumption .", "label": "", "metadata": {}, "score": "63.878387"}
{"text": "In summary , both pilot trials in na\u00efve HIV / HCV co - infected patients have demonstrated statistically superior treatment outcome responses in patients receiving DAA - based HCV therapy over dual therapy with pegIFN / RBV alone .", "label": "", "metadata": {}, "score": "63.941086"}
{"text": "Hepatology 2012 , 55 , 1038 - 1047 .[ Google Scholar ] .Check , P.J. ; Thompson , A.J. ; Vock , D.M. ; Kratz , L.E. ; Tolun , A.A. ; Muir , A.J. ; McHutchison , J.G. ; Subramanian , M. ; Millington , D.M. ; Kelley , R.I. ; et al .", "label": "", "metadata": {}, "score": "64.01601"}
{"text": "When we treat patients infected with HCV in daily clinical practice , it seems important to be aware of the potential treatments of HCV in the near future , as the development of new drugs is always ongoing .", "label": "", "metadata": {}, "score": "64.05622"}
{"text": "In the Fonquernie study , three factors associated with persistently normal ALT levels were identified , namely : HBsAg negativity , HCV genotype 4 and female sex 29 .", "label": "", "metadata": {}, "score": "64.09291"}
{"text": "Indeed , the availability of the first HCV protease inhibitors ( PI ) boceprevir and telaprevir for HCV genotype 1 patients has changed the gold standard of treating hepatitis C allowing for substantially improved HCV cure rates under triple HCV - PI / pegylated interferon / ribavirin therapy .", "label": "", "metadata": {}, "score": "64.15656"}
{"text": "Then we have the other barriers to treatment thrown in : significant medical illness and specifically , very advanced liver disease due to the HCV infection itself .", "label": "", "metadata": {}, "score": "64.16162"}
{"text": "Consequently , HCV treatment of active or former injection drug users is an important area for further investigation .Methadone is commonly used to treat substance abuse , and many HCV - infected former substance abusers are prescribed methadone .", "label": "", "metadata": {}, "score": "64.22623"}
{"text": "Despite treatment with antiretroviral therapy ( ART ) , patients co - infected with HIV and hepatitis C virus ( HCV ) have higher rates of liver decompensation than patients with HCV alone , according to an article being published in Annals of Internal Medicine .", "label": "", "metadata": {}, "score": "64.26508"}
{"text": "In summary , these trials suggest that simplified DAA - based HCV therapy will become available very shortly , promising for a smaller tablet burden , with at least equal efficacy compared to the current triple therapy regimens but with better tolerability .", "label": "", "metadata": {}, "score": "64.2958"}
{"text": ": The interleukin 28B ( IL28B )rs12979860 polymorphism is associated with treatment outcome in hepatitis C virus ( HCV ) genotype 1 and 4 patients .", "label": "", "metadata": {}, "score": "64.45215"}
{"text": "Since most patients with HCV - related chronic hepatitis do not develop cirrhosis , it is logical to infer that host - related and virus - related factors must play a role in the progression to cirrhosis .", "label": "", "metadata": {}, "score": "64.50973"}
{"text": "Hemoglobin is responsible for carrying oxygen to the tissues .A decrease in the hemoglobin concentration results in anemia .A multicenter , double - blind randomized trial was conducted designed to evaluate the effect of recombinant human erythropoietin ( rHuEPO - a drug that is given to increase the hemoglobin concentration ) to : 1 ) maintain ribavirin levels , 2 ) alleviate anemia , and 3 ) improve quality of life .", "label": "", "metadata": {}, "score": "64.59804"}
{"text": "Most studies have shown that in HCV - HIV coinfected patients liver fibrosis progression is faster than in HCV monoinfected patients 16 - 20 .There are few studies that analyze liver histology in HIV - HCV coinfected patients with PNALT .", "label": "", "metadata": {}, "score": "64.59987"}
{"text": "Because the drug toxicities associated with interferon treatment may be severe , many chronically infected patients ( or their physicians ) are reluctant to begin HCV treatment .", "label": "", "metadata": {}, "score": "64.61563"}
{"text": "HIV and hepatitis C viruses share similar rules of transmission leading to a high rate of hepatitis C co - infection among patients with HIV .", "label": "", "metadata": {}, "score": "64.64659"}
{"text": "It is noteworthy , however , that triple therapy studies in HCV treatment - experienced patients ( see the ANRS CO20-CUPIC trial ) also showed good early treatment response rates , which , however , did not translate to high SVR rates after the end of therapy [ 21 ] .", "label": "", "metadata": {}, "score": "64.68166"}
{"text": "Those patients who did not undergo the second biopsy were considered to have no improvement .In terms of the study results , 70 % of the patients with advanced fibrosis ( F3 or F4 ) who were given ADV showed improvement compared with 34 % of those patients in the placebo group .", "label": "", "metadata": {}, "score": "64.700516"}
{"text": "ETS was observed in 80 % of patients with half of these patients being able to stop treatment at Week 24 .This study will provide very interesting data on potentially shorter treatment durations in HIV / HCV co - infected subjects for the first time in the near future .", "label": "", "metadata": {}, "score": "64.75252"}
{"text": "The variables related to cirrhosis development in coinfected patients in according with Benhamou study were similar too 17 .The slower progression of liver fibrosis in coinfected patients with persistently normal ALT levels could be related , in part , to a lower frequency of steatosis in according to the Bani - Sadr study 30 .", "label": "", "metadata": {}, "score": "64.77558"}
{"text": "Very close surveillance should be done to make sure we do n't miss this typically asymptomatic disease .I also believe that HIV treatment guidelines should be changed to include HCV antibody testing for HIV - infected MSM at least once every year .", "label": "", "metadata": {}, "score": "65.03067"}
{"text": "Viewed from the clinical data of first - generation protease inhibitors , telaprevir and boceprevir , these drugs showed potent inhibition of HCV , although they occasionally led to severe adverse events [ 46 , 47 ] .", "label": "", "metadata": {}, "score": "65.03633"}
{"text": "The number of dividing liver cells was decreased in the group after treatment with IFN - alfa .Liver cancer was increased significantly in the group with more dividing liver cells compared with the patients who had few dividing liver cells .", "label": "", "metadata": {}, "score": "65.1297"}
{"text": "The authors concluded that neither PIs nor NNRTIs have an effect on the spectrum of liver disease observed in HIV / HCV co - infected patients and that a large number of co - infected patients have normal ALT .", "label": "", "metadata": {}, "score": "65.388176"}
{"text": "[ Google Scholar ] .Rousselet , M.C. ; Michalak , S. ; Dupr\u00e8 , F. ; Crou\u00e9 , A. ; Bedossa , P. ; Saint - Andr\u00e9 , J.P. ; Cal\u00e8s , P. Sources of variability in histological scoring of chronic viral hepatitis .", "label": "", "metadata": {}, "score": "65.39029"}
{"text": "Qurishi N , Kreuzberg C , L\u00fcchters G , Effenberger W , Kupfer B , Sauerbruch T , Rockstroh JK , Spengler U : Effect of antiretroviral therapy on liver - related mortality in patients with HIV and hepatitis C virus co - infection .", "label": "", "metadata": {}, "score": "65.39624"}
{"text": "J Hepatol 1997 ; 26:1 - 5 .[Links ] .Mohsen AH , Easterbrook PJ , Taylor C , Portmann B , Kulasegaram R , Murad S , et al .", "label": "", "metadata": {}, "score": "65.40956"}
{"text": "Materials and Methods .Patient Population .This study was a sub - analysis of the MIST study , which was originally designed to compare the safety and effectiveness of PegIFN\u03b12a and Peg - IFN\u03b12b therapy with RBV in untreated patients with chronic hepatitis C ( CHC ) [ 21 ] .", "label": "", "metadata": {}, "score": "65.4298"}
{"text": "It 's a similar situation to what had long been the case with antiretrovirals , except that HCV treatment is even more significantly toxic than what we saw in the early days of antiretrovirals .", "label": "", "metadata": {}, "score": "65.48838"}
{"text": "HCV TREATMENT --Clinical significance of pegylated interferon induced neutropenia ; Results from the WIN - R trial .-- Aggressive psychiatric intervention based on clinical suspicion , not standardized depression scores , increases adherence to pegylated interferon and ribavirin therapy for hepatitis C. -- Epoetin alfa treatment of anemic HCV - infected patients allows for maintenance of ribavirin dose .", "label": "", "metadata": {}, "score": "65.57692"}
{"text": "Research Department of Infection , UCL .References .HIV Med 2013 , 14 : 195 - 207 .PubMed View Article .J Infect Dis 2005 , 192 : 992 - 1002 .", "label": "", "metadata": {}, "score": "65.60037"}
{"text": "Hepatology 2012 , 56 , 49 - 56 .[ Google Scholar ] .Bochud , P.Y. ; Cai , T. ; Overbeck , K. ; Bochud , M. ; Dufour , J.F. ; M\u00fcllhaupt , B. ; Borovicka , J. ; Heim , M. ; Moradpour , D. ; Cerny , A. ; et al .", "label": "", "metadata": {}, "score": "65.634445"}
{"text": "In conclusion , milk thistle appears to have limited efficacy in the treatment of HCV as it did not significantly alter ALT , other serum chemistries , or quality of life .", "label": "", "metadata": {}, "score": "65.898254"}
{"text": "Ge D , Fellay J , Thompson AJ , Simon JS , Shianna KV , Urban TJ , Heinzen EL , Qiu P , Bertelsen AH , Muir AJ , Sulkowski M , McHutchison JG , Goldstein DB : Genetic variation in IL28B predicts hepatitis C treatment - induced viral clearance .", "label": "", "metadata": {}, "score": "65.95894"}
{"text": "Optimal duration of dual HCV therapy in HCV / HIV co - infected patients not eligible for triple therapy .Legend : i ) Where no access to DAA is available or high chances of cure even with dual therapy ( favorable IL28B genotype , low HCV viral load and no advanced fibrosis ) .", "label": "", "metadata": {}, "score": "66.053604"}
{"text": "Hepatology 2012 , 55 , 336 - 342 .[ Google Scholar ] .Asselah , T. ; de Muynck , S. ; Bro\u00ebt , P. ; Masliah - Planchon , J. ; Blanluet , M. ; Bi\u00e8che , I. ; Lapalus , M. ; Martinot - Peignoux , M. ; Lada , O. ; Estrabaud , E. ; et al .", "label": "", "metadata": {}, "score": "66.132576"}
{"text": "This enhanced fibrosis progression may be a result of the direct fibrogenetic effect of HIV in the liver and a likely consequence of HIV induced impairment of the innate and adaptive immune system leading to more inflammation , apoptosis and fibrosis [ 5 ] ) .", "label": "", "metadata": {}, "score": "66.17784"}
{"text": "Increases hemoglobin levels , and improves quality of life vs. placebo : a randomized , double - blind , multicenter study .Anemia is a frequent adverse event in patients treated with ribavirin , which can result in a decrease in SVR if RBV dose reduction is required , particularly during the first three months of therapy .", "label": "", "metadata": {}, "score": "66.20067"}
{"text": "Most of these patients have a slow progression of liver fibrosis .Studies have demonstrated the rate of liver fibrosis progression in hepatitis C virus - human immunodeficiency virus ( HCV - HIV ) coinfected patients is faster than in patients infected only by HCV .", "label": "", "metadata": {}, "score": "66.22271"}
{"text": "Thus , SVR rates were higher among patients who had previously had relapses than among nonresponders .Response - guided therapy is also useful in the telaprevir - included regimen ( Table 2 ) [ 40 ] .", "label": "", "metadata": {}, "score": "66.240555"}
{"text": "Hepatology 2012 , 56 , 444 - 454 .[ Google Scholar ] .Thompson , A.J. ; Clark , P.J. ; Zhu , M. ; Zhu , Q. ; Ge , D. ; Sulkowski , M.S. ; Muir , A.J. ; Tillmann , H.L. ; Patel , K. ; Naggie , S. ; et al .", "label": "", "metadata": {}, "score": "66.31263"}
{"text": "Treatment should be determined based on regular monitoring for the development and extent of liver disease .Because of advances in the field of antiviral therapy for chronic hepatitis B and chronic hepatitis C , standards of practice might change , and those with chronic infection should consult with health care providers who are experienced in treating viral hepatitis .", "label": "", "metadata": {}, "score": "66.34256"}
{"text": "MLA Annals of Internal Medicine .\" Patients co - infected with HIV and HCV more likely to suffer liver decompensation .\" Medical News Today .", "label": "", "metadata": {}, "score": "66.378296"}
{"text": "J Hepatol 1997 ; 27:18 - 24 .[Links ] .Saillour F , Dabis F , Dupon M , Lacoste D , Trimoulet P , Rispal P , et al .", "label": "", "metadata": {}, "score": "66.449524"}
{"text": "M\u00c9TODOS : Portadores de coinfec\u00e7\u00e3o VHC - HIV ( HCV - RNA e anti - HIV positivos ) com tempo de infec\u00e7\u00e3o pelo VHC conhecido ( uso de drogas intravenosas ) foram selecionados .", "label": "", "metadata": {}, "score": "66.53281"}
{"text": "Patients with previous null - response and cirrhosis were excluded because of the overall low probability of treatment response .Both studies were presented as pre - planned interim analyses at Week 16 of therapy .", "label": "", "metadata": {}, "score": "66.626854"}
{"text": "HIV Med 2009 ; 10:417 - 421 .[Links ] .Sanchez - Conde M , Berenguer J , Miralles P , Alvarez F , Carlos Lopez J , Cosin J , et al .", "label": "", "metadata": {}, "score": "66.633286"}
{"text": "A higher homocysteine level is also one of factors predicting a nonresponse to treatment [ 28 ] .IL28B SNPs help to improve the treatment outcomes in HCV - patients treated with SOC [ 29 - 34 ] .", "label": "", "metadata": {}, "score": "66.64346"}
{"text": "As previously described , we also found higher levels of serum triglycerides in patients with steatosis , with patients carrying the T allele displaying the highest values .", "label": "", "metadata": {}, "score": "66.85462"}
{"text": "Commentary : While the conclusions of this study were negative , it is well done and rules out an important mechanism that might account for thrombocytopenia .", "label": "", "metadata": {}, "score": "66.87481"}
{"text": "AIDS 2004 ; 18 : 767 - 774 .[Links ] .Qurish N , Kreuzberg C , Luchters G , Effenberger W , Kupfer B , Sauerbruch T , et al .", "label": "", "metadata": {}, "score": "66.99121"}
{"text": "New drugs dangle tantalizingly on the horizon , but they have not yet been investigated in HIV - infected patients .15 The complications of interferon - based therapy are well known and increasingly well documented , 3 - 8 , 18 , 19 leading us to look forward to treatments that are less toxic -- but , again , not in the near future .", "label": "", "metadata": {}, "score": "67.19241"}
{"text": "Links ] .Fonquernie L , Serfaty L , Charrois A , Wendum D , Lefebvre B , Girard PM , et al .Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients .", "label": "", "metadata": {}, "score": "67.23389"}
{"text": "Although several markers that are measured in peripheral blood are being evaluated for their ability to accurately assess the degree of fibrosis , they are not yet sensitive enough to replace the liver biopsy .", "label": "", "metadata": {}, "score": "67.31391"}
{"text": "In chronic hepatitis C patients the definition of persistently normal ALT activity ( PNALT ) no has consensus .Guidelines from the American Association for the Study of Liver Disease suggest that at least two ALT measurements within the normal range taken over at least 6 months can define those with PNALT 34 .", "label": "", "metadata": {}, "score": "67.708984"}
{"text": "Other authors have found that ARV therapy actually may protect against liver damage , although this finding still remains controversial .( editorial note : there were study limitations restricting how much you can conclude from this study .", "label": "", "metadata": {}, "score": "67.727"}
{"text": "Summary of key drug - drug interactions between HIV drugs and the licensed DAAs and dosing recommendations .Taking into consideration all the complex issues surrounding anti - HCV treatment in this group of patients , particularly drug - drug interactions and side - effects , it is important that these patients are managed in centers with experience in managing HCV / HIV co - infected patients .", "label": "", "metadata": {}, "score": "67.776474"}
{"text": "Cirrhosis rates become significant after 20 years of HCV infection .About 20 - 30 % of patients could develop a progressive liver disease leading to cirrhosis and HCC [ 5 , 7 ] .", "label": "", "metadata": {}, "score": "67.9319"}
{"text": "92 % of the patients were taking a mean of 3 antiretroviral medications , 98 % were on nucleoside reverse transcriptase inhibitors ( NRTI ) , 45 % were taking nonnucleoside reverse transcriptase inhibitors ( NNRTI ) and 54 % were taking protease inhibitors ( PI ) .", "label": "", "metadata": {}, "score": "67.95038"}
{"text": "Approximately 60 % of the patients who are treated with pegylated interferon and ribavirin will fail to have a viral response to therapy .However the question remains whether they will achieve improvement in liver histology .", "label": "", "metadata": {}, "score": "67.96413"}
{"text": "14 There was , however , a statistically significant difference in mean hemoglobin levels at week 4 -- in favor of the high - dose ribavirin arm .", "label": "", "metadata": {}, "score": "67.97706"}
{"text": "Mean CD4 counts dropped the higher the alcohol use category was .Advertisement .Because the study was conducted at VA facilities , participants were predominantly male and black , which may limit the applicability of results to the wider population .", "label": "", "metadata": {}, "score": "67.998795"}
{"text": "Rapid virologic response rates in the high - dose ribavirin group were not noted to be superior to the standard - dose ribavirin group ; 22 % of patients in each arm achieved rapid virologic response .", "label": "", "metadata": {}, "score": "68.02692"}
{"text": "A total of 42 % of the patients received concomitant EPO .Both of these studies show very impressive early treatment response rates independent of baseline fibrosis stage ( please note that patients with prior null - response and F4 fibrosis , however , were excluded from the trial ) .", "label": "", "metadata": {}, "score": "68.045944"}
{"text": "That excessive alcohol consumption is bad for anyone 's liver is well known .However , the specific risks associated with different patterns of alcohol use , especially among those infected with HIV , hepatitis C ( HCV ) or both , are not so well established .", "label": "", "metadata": {}, "score": "68.20305"}
{"text": "The primary endpoint of the study is SVR12 .Overall , 304 ( 239 treatment na\u00efve and 69 relapsers ) patients were included , making this the largest co - infection DAA study so far .", "label": "", "metadata": {}, "score": "68.312485"}
{"text": "IL28B genotype is associated with the histological features of chronic hepatitis C in a HCV genotype dependent manner , with CC genotype being independently associated with severe portal inflammation .", "label": "", "metadata": {}, "score": "68.32117"}
{"text": "HCV is transmitted when people share drug solution , syringes , and other drug use equipment ( water , drug solution containers , and cotton filters ) that are contaminated with HCV - infected blood .", "label": "", "metadata": {}, "score": "68.34006"}
{"text": "[ Google Scholar ] .Rev. Soc .Bras .Med .Trop .vol.45 no.4 Uberaba jul./ago .Liver fibrosis progression in HIV / hepatitis C virus coinfected patients with normal aminotransferases levels .", "label": "", "metadata": {}, "score": "68.43438"}
{"text": "Exclusion criteria were co - infection with hepatitis B virus and/or human immunodeficiency virus , drug dependence , elevated alcohol intake , autoimmune hepatitis and/or any other liver disease and decompensated liver disease .", "label": "", "metadata": {}, "score": "68.44023"}
{"text": "Backus LI , Boothroyd DB , Phillips BR , Belperio P , Halloran J , Mole LA : A sustained virologic response reduces risk of all - cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011 , 9 : 509 - 516 .", "label": "", "metadata": {}, "score": "68.50007"}
{"text": "Eur J Med Res 2009 , 14 : 507 - 515 .PubMed Central PubMed View Article .HIV Med 2013 , 14 : 614 - 623 .", "label": "", "metadata": {}, "score": "68.51277"}
{"text": "Gastroenterology 2010 , 139 , 120 - 129 .[ Google Scholar ] .Mangia , A. ; Thompson , A.J. ; Santoro , R. ; Piazzolla , V. ; Tillmann , H.L. ; Patel , K. ; Shianna , K.V. ; Mottola , L. ; Petruzzellis , D. ; Bacca , D. ; et al .", "label": "", "metadata": {}, "score": "68.56908"}
{"text": "We do hope however that these latter drawbacks were attenuated by the fact that histological readings were carried out on liver cores of appropriate length by two independent experts who were blind to the demographic data .", "label": "", "metadata": {}, "score": "68.72621"}
{"text": "In this trial , 27 HIV / HCV - coinfected patients who were receiving antiretroviral therapy that included abacavir were examined .Specifically , no significant differences between the patients who received or did not receive abacavir as part of their ARV ( antiretroviral ) backbone were found .", "label": "", "metadata": {}, "score": "68.73691"}
{"text": "Todos receberam terapia antirretroviral .Os n\u00edveis de ALT foram persistentemente normais em 13 ( 26 % ) pacientes .CONCLUS\u00d5ES : Portadores de coinfec\u00e7\u00e3o VHC - HIV com APNL apresentam progress\u00e3o mais lenta da fibrose hep\u00e1tica .", "label": "", "metadata": {}, "score": "68.75047"}
{"text": "Em portadores de coinfec\u00e7\u00e3o VHC - HIV , estudos t\u00eam demonstrado que a progress\u00e3o da fibrose hep\u00e1tica \u00e9 mais r\u00e1pida que a observada em indiv\u00edduos infectados somente pelo VHC .", "label": "", "metadata": {}, "score": "68.810104"}
{"text": "The decay of HCV RNA in genotype 1 infected patients in response to treatment with interferon and ribavirin has been useful in predicting those patients who are likely to respond compared with those who are not .", "label": "", "metadata": {}, "score": "68.88233"}
{"text": "The more recent entrants , however , had become HIV infected predominantly through sexual transmission ( IDU prevalence was 67 % in 1997 versus 15 % in 2006 ) .", "label": "", "metadata": {}, "score": "68.92456"}
{"text": "ALT had poor accuracy in predicting the severity of liver injury , indicating that a liver biopsy is essential to identify those with advanced fibrosis who might benefit from anti - HCV therapy .", "label": "", "metadata": {}, "score": "68.929565"}
{"text": "The YMDD mutation ( specific for ADV ) was present in 100 % of the patients enrolled in the study .( Note : A 4 log10 decrease is a decrease by 4-tens places .", "label": "", "metadata": {}, "score": "69.1346"}
{"text": "Prior to 1987 , clotting factor was not heat inactivated , so almost all hemophiliacs who received clotting factor before that date have been exposed to HCV .", "label": "", "metadata": {}, "score": "69.186775"}
{"text": "LBs were considered adequate for histological analysis if they were longer than 10 mm and/or had at least 12 portal tracts .Liver fibrosis stage was evaluated semi - quantitatively according to the METAVIR scoring system [ 23 , 24 ] .", "label": "", "metadata": {}, "score": "69.22281"}
{"text": "Sofosbuvir plus peginterferon / ribavirin in treatment - naive patients with HCV genotype 1 leads to higher RVR rates and SVR rates than SOC ( 88 - 94 % vs. 21 % ; and 56 - 83 % vs. 43 % , respectively ) [ 58 ] .", "label": "", "metadata": {}, "score": "69.23687"}
{"text": "Hepatology 2009 , 50 : 407 - 413 .PubMed View Article .Clin Infect Dis 2012 , 55 : 728 - 736 .PubMed View Article .", "label": "", "metadata": {}, "score": "69.23815"}
{"text": "Those who do have symptoms might experience : .Most people who become infected as adults or older children recover fully from the infection and develop protective immunity to the virus .", "label": "", "metadata": {}, "score": "69.39374"}
{"text": "To further strengthen the robustness of our correlation study , we elected to assess necroinflammatory activity by both METAVIR and Ishak grading scores , with the hope that the latter would allow a more accurate definition of lobular topography of the necroinflammatory changes .", "label": "", "metadata": {}, "score": "69.45592"}
{"text": "Grade 3 to 4 anemia , erythropoietin ( EPO ) use , transfusion or RBV dose reduction was recorded in 61 % of patients .The second ANRSstudy looked at the efficacy and safety of a boceprevir containing triple therapy in 64 previous IFN / RBV non - responders [ 13 ] .", "label": "", "metadata": {}, "score": "69.63662"}
{"text": "Clin Infect Dis 2004 ; 38:128 - 133 .[Links ] .Benhamou Y , Di Martino V , Bochet M , Colombet G , Thibault V , Liou A , et al .", "label": "", "metadata": {}, "score": "69.70899"}
{"text": "The current analysis from this study lacks reliable information upon which to draw conclusion regarding the effect of PI or NNRTI based HAART on the liver .", "label": "", "metadata": {}, "score": "69.72813"}
{"text": "IL28B genotype was CC in 117 ( 34 % ) , CT in 166 ( 49 % ) and TT in 52 ( 15 % ) .", "label": "", "metadata": {}, "score": "70.32649"}
{"text": "If you have or suspect you may have a health problem , consult your health care provider .--- Our top categories - Alzheimer 's / Dementia - Breast Cancer - Cancer / Oncology - Diabetes - Ebola - HIV / AIDS - Infectious Diseases - Multiple Sclerosis - Nutrition / Diet - Parkinson 's Disease - Stem Cell Research --- View all categories .", "label": "", "metadata": {}, "score": "70.432755"}
{"text": "T1204 .Effect of silybum marianum on serum ALT and well - being in chronic hepatitis C. Many patients who are infected with HCV try \" alternative treatments \" to try to treat the infection .", "label": "", "metadata": {}, "score": "70.436104"}
{"text": "Hepatology 2001 ; 34 : 283 - 287 .[Links ] .Macias J , Castellano V , Merchante N , Palacios RB , Mira JA , Saez C , et al .", "label": "", "metadata": {}, "score": "70.44794"}
{"text": "However , with careful monitoring by a health care team experienced in hepatitis , addiction , and other pertinent conditions , IDUs can be successfully treated .", "label": "", "metadata": {}, "score": "70.552536"}
{"text": "However , significant drop - out rates as a result of SAEs were not seen by Week 16 .Moreover , in the CUPIC trial , there was a considerable incidence of severe complications and death , especially in patients with low platelet counts and low albumin .", "label": "", "metadata": {}, "score": "70.56803"}
{"text": "While an apparent cure for HCV infection is tantalizing , this \" treatment , \" HBV to cure hepatitis C , would be extreme -- particularly given the coinfected patient who died and the patient who required liver transplantation .", "label": "", "metadata": {}, "score": "70.600525"}
{"text": "No interim results from these studies , however , have been publically presented to date .Who to treat now , where to wait ?Therefore , the first essential step in HCV treatment decision - making is fibrosis stage assessment , as the current fibrosis stage of a patient reliably predicts subsequent clinical risk of developing relevant liver disease .", "label": "", "metadata": {}, "score": "70.734085"}
{"text": "DDW Liver Conference Report Written by Andrew Talal , MD , MPH , Cornell - Weill Medical Center GI & Hepatitis Clinic .-- Interferon and interferon plus ribavirin in hepatocellular carcinoma prevention .", "label": "", "metadata": {}, "score": "70.74849"}
{"text": "Interferon is clearly associated with significant neutropenia , as well as a decline in CD4 + cell count ( sometimes to below 200 copies / mL ) , which dramatically increases a patient 's risk for developing comorbidities .", "label": "", "metadata": {}, "score": "70.952156"}
{"text": "This study is important because it demonstrates that methadone does not impair the antiviral activity of IFN and that IFN - alfa does not significantly alter methadone concentrations .", "label": "", "metadata": {}, "score": "71.02452"}
{"text": "The objective of this study was to evaluate the effect of switching LAM to ADV or adding ADV to LAM compared with continuing LAM in hepatitis E antigen positive HBV - infected patients .", "label": "", "metadata": {}, "score": "71.040146"}
{"text": "Several years ago , when the drug was used as a treatment for HIV , the drug was eventually taken off the market because of kidney problems .", "label": "", "metadata": {}, "score": "71.048164"}
{"text": "The problem with the long - term use of 3TC is that most patients will become resistant to it ( up to 90 % at 4 years ) .", "label": "", "metadata": {}, "score": "71.08217"}
{"text": "It 's also spread through high - risk sexual behaviors , such as unprotected sex with multiple partners .Injection drug users ( IDUs ) with high - risk sexual and druguse behaviors are at high risk of HBV infection .", "label": "", "metadata": {}, "score": "71.369965"}
{"text": "N Engl J Med 1998 ; 338:853 - 860 .[Links ] .Bica I , McGovern B , Dhar R , Stone D , McGowan K , Scheib R , et al .", "label": "", "metadata": {}, "score": "71.38984"}
{"text": "Interest in viral hepatitis , especially hepatitis C , is growing but there is still a great need to educate the general public and health professionals about preventing , testing , and treating hepatitis C. This is particularly true in light of the fact that treatment is expensive and adherence over the 6 - 12 months of treatment can be difficult .", "label": "", "metadata": {}, "score": "71.40341"}
{"text": "Among the DAA anti - HCV drugs , the three most likely to be licensed in 2014 is the once - daily nucleotide analogue HCV polymerase inhibitor sofosbuvir , as well as the second - wave , once - daily HCV protease inhibitors simeprevir and faldaprevir .", "label": "", "metadata": {}, "score": "71.46011"}
{"text": "METHODS : HCV - HIV coinfected patients ( HCV - RNA and anti - HIV positive ) with known time of HCV infection ( intravenous drugs users ) were selected .", "label": "", "metadata": {}, "score": "71.54039"}
{"text": "Conclusion .HCV therapy has also dramatically changed with the advent of the first DAAs in the HIV / HCV co - infected population with the promise of much higher cure rates and potentially shortened treatment durations .", "label": "", "metadata": {}, "score": "71.540955"}
{"text": "Palavras - chaves : Cirrose hep\u00e1tica .Hepatite C. HIV .Aminotransferases .Due to shared risk factors for transmission of coinfection with human immunodeficiency virus ( HIV ) and hepatitis C virus ( HCV ) it is a very common event .", "label": "", "metadata": {}, "score": "71.54555"}
{"text": "[ Google Scholar ] .[ Google Scholar ] .[ Google Scholar ] [ CrossRef ] .Bedossa , P. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994 , 20 , 15 - 20 .", "label": "", "metadata": {}, "score": "71.62748"}
{"text": "296 .[Links ] .Many individuals who become infected with hepatitis B virus ( HBV ) or hepatitis C virus ( HCV ) develop chronic liver disease that can gradually lead to serious liver damage .", "label": "", "metadata": {}, "score": "71.71305"}
{"text": "Morbidity and mortality from co - morbid hepatitis C ( HCV ) infection in HIV co - infected patients are increasing ; hence , the management of hepatitis co - infection in HIV is now one of the most important clinical challenges .", "label": "", "metadata": {}, "score": "71.80394"}
{"text": "A phase IIa , randomized , double - blind , placebo - controlled study in 62 HCV / HIV co - infected patients investigated the safety and efficacy of telaprevir in combination with PegIFN - \u03b1-2a and 800 mg RBV ( US ) and weight - based dose RBV in France and Germany [ 11 ] ) .", "label": "", "metadata": {}, "score": "71.899506"}
{"text": "IL28B CC patients , in fact , display a more pronounced activity of natural killer ( NK ) cells that are instrumental to viral clearance following treatments based on immunomodulatory drugs such as IFN and RBV [ 12 , 13 ] .", "label": "", "metadata": {}, "score": "71.97876"}
{"text": "The presenter reminded the audience that in an uncontrolled trial that was presented at AASLD in 2002 , children who were treated with interferon combined with ribavirin syrup achieved an SVR of 57 % .", "label": "", "metadata": {}, "score": "72.00464"}
{"text": "Patients were considered to have normal ALT if they had at least 3 normal determinations ( lower than the upper limit of normal ) in the previous 6 months prior to liver biopsy were included in Group 1 ( G1 ) .", "label": "", "metadata": {}, "score": "72.13886"}
{"text": "While we 're on the topic of standard - of - care practices for patients with hepatitis C coinfection , there was one study at ICAAC / IDSA 2008 that addressed the importance of vaccination against hepatitis B ( HBV ) in patients who have chronic hepatitis C infection .", "label": "", "metadata": {}, "score": "72.290344"}
{"text": "Overall , the combination of methadone and IFN - alfa were well tolerated , there were no serious adverse events during the course of the study and none of the patients required methadone dose modification .", "label": "", "metadata": {}, "score": "72.35942"}
{"text": "From a clinician 's perspective this calls for practical clinical algorithms which could help in the day - to - day management of these patients .", "label": "", "metadata": {}, "score": "72.38495"}
{"text": "There are , however , only two protease inhibitors in advanced clinical trials for HCV therapy : telaprevir and boceprevir .Neither is an ideal candidate : They both require dosing multiple times a day ( there are a few protease inhibitors coming along that have perhaps once - a - day dosing , but they are , at best , in the very early stages of development ) .", "label": "", "metadata": {}, "score": "72.42023"}
{"text": "While this is a strongly optimistic note that there are fewer HCV transmissions occurring now thanks to less injection drug use , I have to add a strong cautionary note .", "label": "", "metadata": {}, "score": "72.60251"}
{"text": "Authors ' information .JKR is a Professor of Medicine at the University of Bonn where he heads the HIV outpatient clinic .Sanjay Bhagani is a Consultant Physician in Infectious Diseases and HIV Medicine at the Royal Free Hospital , London where he leads a multi - disciplinary HIV / hepatitis co - infection clinic and is an honorary Senior Lecturer at UCL .", "label": "", "metadata": {}, "score": "72.68636"}
{"text": "Hepatology 2010 , 52 , 1220A. [ Google Scholar ] .Rembeck , K. ; Alsio , A. ; Christensen , P.B. ; F\u00e4rkkil\u00e4 , M. ; Langeland , N. ; Buhl , M.R. ; Pedersen , C. ; M\u00f8rch , K. ; Westin , J. ; Lindh , M. ; et al .", "label": "", "metadata": {}, "score": "72.700775"}
{"text": "Boceprevir was discontinued in all patients with a HCV viral load above 1,000 IU / ml at Week 8 and/or at Week 12 .Patients recruited for the trial had to be on stable ART for at least three months , with at least three molecules among ATV ( ritonavir boosted or not ) , RAL , TDF , ABC , FTC or 3TC .", "label": "", "metadata": {}, "score": "72.71626"}
{"text": "To assess the correlation between IL28B genotype , HCV genotype and liver biopsy findings in untreated patients .Materials and Methods .IL28B was typed by Taqman Single Nucleotide Polymorphism ( SNP ) genotyping assay .", "label": "", "metadata": {}, "score": "72.845474"}
{"text": "During his presentation , Dr. Thomas also discussed important antiretroviral management strategies to employ during hepatitis C treatment .He reminded us that didanosine ( ddI , Videx ) should not be used concurrently with ribavirin treatment due to significant toxicity .", "label": "", "metadata": {}, "score": "73.09688"}
{"text": "Early virologic response to interferon and ribavirin treatment in patients co - infected with HCV and HIV .It is known that patients with HCV who have a virologic response to IFN and ribavirin usually respond within the first 12 weeks .", "label": "", "metadata": {}, "score": "73.37851"}
{"text": "If you have or suspect you may have a health problem , consult your health care provider .Abstract .Two direct - acting antivirals ( DAAs ) against hepatitis C virus ( HCV ) : telaprevir and boceprevir , are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection .", "label": "", "metadata": {}, "score": "73.55862"}
{"text": "Gut 2003 ; 52:1035 - 1040 .[Links ] .Martin - Carbonero L , Benhamou Y , Puoti M , Berenguer J , Mallolas J , Quereda C , et al .", "label": "", "metadata": {}, "score": "73.59143"}
{"text": "The aim of this study was to evaluate the effect of steatosis ( fat in the liver ) on the outcome of treatment for HCV .", "label": "", "metadata": {}, "score": "73.95197"}
{"text": "The combination of two non invasive tools provide a useful system for the assessment of fibrosis evolution in patients with HIV - HCV coinfection .[ Show abstract ] [ Hide abstract ] ABSTRACT : Due to a recent alarming increase in the number of HIV - HCV co - infected patients in Romania .", "label": "", "metadata": {}, "score": "73.97345"}
{"text": "Another tool that was used to measure quality of life , the SF-36 , was also significantly improved in the group that received rHuEPO .After cross - over , the group that had initially received placebo also had an improvement in the quality of life .", "label": "", "metadata": {}, "score": "73.98271"}
{"text": "Patients were required to be receiving no antiretrovirals ( part A ) or one of two specified antiretroviral regimens ( part B ) , including either efavirenz or ritonavir boosted atazanavir .", "label": "", "metadata": {}, "score": "74.07887"}
{"text": "Clin Infect Dis 2006 ; 43:640 - 644 .[Links ] .Karmen A , Wroblewski F , Ladue JS .Transaminase activity in human blood .", "label": "", "metadata": {}, "score": "74.17088"}
{"text": "[ Google Scholar ] .Naggie , S. ; Osinusi , A. ; Katsounas , A. ; Lempicki , R. ; Herrmann , E. ; Thompson , A.J. ; Clark , P.J. ; Patel , K. ; Muir , A.J. ; McHutchison , J.G. ; et al .", "label": "", "metadata": {}, "score": "74.23342"}
{"text": "After Week 4 , telaprevir was added for12 weeks .Telaprevir was administered as 750 mg q8h ( 1,125 mg q8h with EFV ) and pegIFN \u03b1-2a as 180 \u03bcg sc / week .", "label": "", "metadata": {}, "score": "74.53695"}
{"text": "Conference on Retroviruses and Opportunistic Infections , Atlanta 2013 . abstract 36 .20thConference on Retroviruses and Opportunistic Infections , Atlanta 2013 . abstract 37 .", "label": "", "metadata": {}, "score": "74.5952"}
{"text": "Table 6 .New drugs for the treatment of hepatitis C in phase III study ( combinations with peginterferon plus ribavirin , or DAA combinations ) .", "label": "", "metadata": {}, "score": "74.767944"}
{"text": "( Comment : Loss of the YMDD mutation means that the patients are no longer resistant to LAM .The fact that a considerable number of the patients who got ADV alone lost the YMDD mutation is an important finding ) .", "label": "", "metadata": {}, "score": "74.787056"}
{"text": "AIDS 2003 ; 17:1803 - 1809 .[Links ] .Mocroft A , Vella S , Benfield TL , Chiesi A , Miller V , Gargalianos P , et al .", "label": "", "metadata": {}, "score": "74.809105"}
{"text": "[ Google Scholar ] .Golden - Mason , L. ; bambha , K.M. ; Cheng , L. ; Howell , C.D. ; Taylor , M.W. ; Clark , P.J. ; Afdhal , N. ; Rosen , H.R. On behalf of the Virahep - C study group .", "label": "", "metadata": {}, "score": "75.03993"}
{"text": "Definition of histological features and liver disease progression in individuals with HCV and normal ALT is complicated because the absence of a gold standard definition for PNALT .", "label": "", "metadata": {}, "score": "75.054794"}
{"text": "Two NS3 - 4A protease inhibitors , telaprevir and boceprevir , were the first DAAs to become approved in Europe and the United States in 2011 in combination with pegIFN - \u03b1 and RBV for the treatment of HCV genotype 1 infection .", "label": "", "metadata": {}, "score": "75.05652"}
{"text": "The triple combination therapy of telaprevir or boceprevir plus ribavirin and peginterferon - alfa is the NSOC treatment for chronic HCV genotype 1-infected patients [ 35 - 42 ] .", "label": "", "metadata": {}, "score": "75.2902"}
{"text": "Further studies should be performed to follow - up on these results to see if they are confirmed in other prospective trials .HIV / HCV CO - INFECTION 249 .", "label": "", "metadata": {}, "score": "75.31325"}
{"text": "These investigators found that the levels of two enzymes in particular , PIIIP and TIMP-1 were significantly decreased in viral responders compared with nonresponders comparing baseline values with values at the end of treatment .", "label": "", "metadata": {}, "score": "75.31729"}
{"text": "ICAAC / IDSA 2008 ( the 48th Annual ICAAC / IDSA 46th Annual Meeting ) was an enormous combined meeting , but as it was mostly about microbiology , there were n't many posters or talks devoted to hepatitis C in HIV - infected people .", "label": "", "metadata": {}, "score": "75.33655"}
{"text": "Lamivudine ( 3TC - LAM ) has been the standard therapy for active HBV infection for the past several years .However , one of the limitations of 3TC therapy has been the development of resistance , which occurs in approximately 70 % of HBV mono- and 85 - 90 % of HBV / HIV co - infected patients after 3 - 4 years of treatment with the drug .", "label": "", "metadata": {}, "score": "75.338104"}
{"text": "In addition , Dr. Thomas mentioned two observational studies ( which have , to my knowledge , not yet been published ) suggesting that concurrent abacavir ( ABC , Ziagen ) treatment was associated with a worse prognosis for hepatitis C treatment .", "label": "", "metadata": {}, "score": "75.47743"}
{"text": "Direct - acting antivirals ( DAAs ) against HCV are classified into several categories : 1 ) HCV NS3/4A protease inhibitors , 2 ) HCV NS5B polymerase inhibitors , 3 ) HCV NS5A inhibitors , and others .", "label": "", "metadata": {}, "score": "75.72934"}
{"text": "Genet 2009 , 41 , 1105 - 1109 .[ Google Scholar ] .Thompson , A.J. ; Muir , A.J. ; Sulkowski , M.S. ; Ge , D. ; Fellay , J. ; Shianna , K.V. ; Urban , T. ; Afdhal , N.H. ; Jacobson , I.M. ; Esteban , R. ; et al .", "label": "", "metadata": {}, "score": "75.80432"}
{"text": "The relationship between HIV and cardiovascular risk may have special ramifications for HIV / HCV - coinfected patients .Although the reasons for HIV 's cardiovascular effects have not yet been well delineated , given the high prevalence of HCV coinfection among HIV - infected patients , some wonder whether the possible increase in cardiovascular complications may be due at least in part to HCV coinfection .", "label": "", "metadata": {}, "score": "75.80774"}
{"text": "--Efficacy of daily interferon in combination with ribavirin in patients with chronic hepatitis C : Final results of a VA multicenter study .--Early viral kinetics in chronic hepatitis C virus genotype 4 infection .", "label": "", "metadata": {}, "score": "75.81261"}
{"text": "Lancet 2003 ; 362:1708 - 1713 .[Links ] .Zylberberg H , Pialoux G , Carnot F , Landau A , Brechot C , Pol S. Rapidly evolving hepatitis C virus - related cirrhosis in a human immunodeficiency virus - infected patient receiving triple antiretroviral therapy .", "label": "", "metadata": {}, "score": "76.08832"}
{"text": "A French study by Bani - Sadr et al , coinfected patients with persistently normal ALT levels were defined as those having three consecutive persistently normal ALT levels over a 6-month period 30 the same criteria adopted in this study .", "label": "", "metadata": {}, "score": "76.19363"}
{"text": "The addition of boceprevir to SOC results in higher SVR rates in both treatment - na\u00efve and re - treated patients infected with HCV genotype 1 ( Table 3 ) [ 41 , 42 ] .", "label": "", "metadata": {}, "score": "76.21794"}
{"text": "PubMed View Article .N Engl J Med 2004 , 351 : 438 - 450 .PubMed View Article .AIDS Res Hum Retroviruses 2007 , 23 : 972 - 982 .", "label": "", "metadata": {}, "score": "76.24632"}
{"text": "It has been suggested that ART slows HCV - associated liver fibrosis .However , whether rates of hepatic decompensation and other severe liver events in co - infected patients receiving ART are similar to those with HCV only remains unclear .", "label": "", "metadata": {}, "score": "76.248184"}
{"text": "In their retrospective study , Dr. Moreno et al administered the alfa-2a preparation to 93 patients and the alfa-2b preparation to 81 patients .16No differences in early or sustained virological response were seen between the two arms , nor did they note any difference in terms of toxicity .", "label": "", "metadata": {}, "score": "76.39978"}
{"text": "CONFLICT OF INTEREST .The authors declare that there is no conflict of interest .REFERENCES .Greub G , Ledergerber B , Battegay M , Grob P , Perrin L , Furrer H , et al .", "label": "", "metadata": {}, "score": "76.42758"}
{"text": "One of the recurring issues debated when attempting to decide whether to begin HCV treatment in HIV / HCV - coinfected patients is whether the toxicity of interferon and ribavirin treatment outweighs the benefits of therapy .", "label": "", "metadata": {}, "score": "76.601585"}
{"text": "This study was conducted using samples derived from AIDS Clinical Trials Group study 5071 , a randomized trial comparing pegylated interferon alfa-2a and ribavirin to standard interferon and ribavirin .", "label": "", "metadata": {}, "score": "76.60587"}
{"text": "Commentary : This study shows , as have other studies , that IFN - alfa monotherapy can prevent liver cancer .However , the small number of patients who developed liver cancer comparing those who were treated with IFN monotherapy and those who were treated with IFN and RBV limits the conclusions that can be drawn as to whether one drug or two are better able to prevent liver cancer .", "label": "", "metadata": {}, "score": "76.64093"}
{"text": "In SLAM - C , patients who did not have an early virological response to HCV therapy were randomized to either continue or discontinue their interferon and ribavirin treatment .", "label": "", "metadata": {}, "score": "76.666794"}
{"text": "Patients in arm A were treated with faldaprevir at 120 mg / pegIFN / RBV for 24 weeks ; Arm B : faldaprevir at 240 mg / PegIFN / RBV for 12 weeks then re - randomization at Week 12 to a further 12 weeksof faldaprevir / pegIFN / RBV or pegIFN / RBV alone .", "label": "", "metadata": {}, "score": "76.739685"}
{"text": "There was also a significant inverse association between fibrosis score and IFN gamma secretion in response to NS5 .There was no association between IL10 secretion and inflammation or fibrosis .", "label": "", "metadata": {}, "score": "76.951904"}
{"text": "Table 1 .Standard of care treatment and sustained virological response rates for chronic hepatitis C patients .New standard of care ( NSOC ) treatment for HCV infection .", "label": "", "metadata": {}, "score": "76.95711"}
{"text": "In 2011 , the Food and Drug Administration ( FDA ) approved the use of the first two DAAs , boceprevir and telaprevir , for the treatment of HCV genotype 1 infection in mono - infected patients .", "label": "", "metadata": {}, "score": "76.95849"}
{"text": "PREDICTORS OF RESPONSE TO INTERFERON - BASED THERAPY --Steatosis influences the early virologic response rate in patients with chronic hepatitis C infection .HIV / HCV CO - INFECTION --The impact of protease inhibitors ( PI ) on the histologic spectrum of liver disease in HCV - HIV co - infection .", "label": "", "metadata": {}, "score": "77.140656"}
{"text": "Low ribavirin levels in the blood have been associated with a worse treatment outcome .Previous studies have attempted to increase the ribavirin dose in hopes of improving treatment outcomes , but this has resulted in an increase in toxicity ( especially anemia ) .", "label": "", "metadata": {}, "score": "77.16225"}
{"text": "The FDA has approved three antiviral therapies for treatment of chronic hepatitis C in persons 18 years and older : alpha interferon , pegylated interferon , and alpha or pegylated interferon in combination with ribavirin .", "label": "", "metadata": {}, "score": "77.18286"}
{"text": "At the same time , no difference was seen based on whether patients received a PI ( protease inhibitor)-based regimen ; therefore , the researchers felt the results potentially implicated ritonavir - boosted regimens in particular .", "label": "", "metadata": {}, "score": "77.20395"}
{"text": "Although rather rare in this country , genotype 4 is relatively common in Egypt and in Southern Europe .The goal of this study was to determine whether viral kinetics can be used to predict whether genotype 4 patients are likely to achieve a therapeutic response to interferon and ribavirin .", "label": "", "metadata": {}, "score": "77.30621"}
{"text": "In the near future , all - oral DAAs will treat HCV - infected patients ( Figure 1 ) .Conclusions .We expect that all - oral DAAs and interferon - free regimens will be applied in the treatment of HCV - infected patients and that they will have more potent efficacy and less adverse events .", "label": "", "metadata": {}, "score": "77.351456"}
{"text": "Patients were considered to have a normal ALT levels if they had at least 3 normal determinations in the previous 6 months prior to liver biopsy .", "label": "", "metadata": {}, "score": "77.548996"}
{"text": "In that study , IL28B CC patients had higher serum lipid levels that were thought to result from faster conversion of VLDL to LDL induced by the lipoprotein lipase activity .", "label": "", "metadata": {}, "score": "77.802734"}
{"text": "These patients will have to wait for the development of new agents that have specific action against HCV .In the case of severe liver disease , these patients should be considered for maintenance therapy with low dose PEG IFN alfa monotherapy usually given for an extended period of time .", "label": "", "metadata": {}, "score": "77.83559"}
{"text": "LAM was given at a dose of 100 mg per day and ADV was given at a dose of 10 mg per day .Patients were treated for a total of 48 weeks .", "label": "", "metadata": {}, "score": "78.12735"}
{"text": "--Effect of therapy with pegylated interferon - alfa on platelet activation and apoptosis in patients with chronic hepatitis C. --Non - invasive assessment of fibrosis resolution / progressive in chronic hepatitis C patients who received anti - viral therapy .", "label": "", "metadata": {}, "score": "78.177414"}
{"text": "[ Google Scholar ] .Tillmann , H.L. ; Patel , K. ; Muir , A.J. ; Guy , C.D. ; Li , J.H. ; Lao , X.Q. ; Thompson , A. ; Clark , P.J. ; Gardner , S.D. ; McHutchison , J.G. ; et al .", "label": "", "metadata": {}, "score": "78.2597"}
{"text": "Thomas , D.L. ; Thio , C.L. ; Martin , M.P. ; Qi , Y. ; Ge , D. ; O'hUigin , C. ; Kidd , J. ; Kidd , K. ; Khakoo , S.I. ; Alexander , G. ; et al .", "label": "", "metadata": {}, "score": "78.320114"}
{"text": "Nature 2009 , 461 , 399 - 401 .[ Google Scholar ] .Suppiah , V. ; Moldovan , M. ; Ahlenstiel , G. ; Berg , T. ; Weltman , M. ; Abate , M.L. ; Bassendine , M. ; Spengler , U. ; Dore , G.J. ; Powell , E. ; et al .", "label": "", "metadata": {}, "score": "78.55859"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Hepatic inflammation may affect the performance of FibroScan .Inflammation has a significant influence on LSM values in patients with chronic hepatitis B with mild fibrosis , but not in those with significant fibrosis .", "label": "", "metadata": {}, "score": "78.577805"}
{"text": "It is important to ensure that all co - medications , and not just cART components , that patients are on are documented and scrutinized for potential drug - drug interactions with the new DAAs .", "label": "", "metadata": {}, "score": "78.58953"}
{"text": "The issue of whether ribavirin is required in adolescents will necessitate further evaluation .Avoidance of RBV , a potential agent that can cause birth defects , in adolescent females may be advisable unless absolutely required .", "label": "", "metadata": {}, "score": "78.75339"}
{"text": "The etiology ( cause ) of neutropenia in cirrhotics remains to be fully defined , although there are marked differences in the immune system between individuals with advanced scarring of the liver and those with cirrhosis .", "label": "", "metadata": {}, "score": "78.79178"}
{"text": "[Links ] .Pradat P , Alberti A , Poynard T , Esteban JI , Weiland O , Marcellin P , et al .Predictive value of ALT levels for histologic findings in chronic hepatitis C : a European collaborative study .", "label": "", "metadata": {}, "score": "79.34313"}
{"text": "In patients with ALT levels less than 2 times the upper limit of normal , response rates are poor and therapy should be deferred .Antiviral Therapy for Chronic Hepatitis C .", "label": "", "metadata": {}, "score": "79.53137"}
{"text": "Yet morbidity and mortality from HCV - related liver disease are a big problem .How do we solve this problem ?Well , we have no hope of interferon - less therapy in the next decade so the toxicity problem is fixed for the foreseeable future , instead we might have to rethink when to treat .", "label": "", "metadata": {}, "score": "79.73147"}
{"text": "From June 2001 to June 2004 , there were , HCV - HIV coinfected patients followed in Federal University of S\u00e3o Paulo , Brazil , based on serum antibody detection with a third generation enzyme - linked immunosorbent assay .", "label": "", "metadata": {}, "score": "79.95429"}
{"text": "Nature 2009 , 461 , 798 - 801 .[ Google Scholar ] .Rauch , A. ; Kutalik , Z. ; descombes , P. ; Cai , T. ; Iulio , J.D. ; Mueller , T. ; Bochud , M. ; Battegay , M. ; Bernasconi , E. ; Borovicka , J. ; et al .", "label": "", "metadata": {}, "score": "79.968506"}
{"text": "Adverse events : One patient during the study had a transient increase in ALT .The patient was able to continue on therapy and eventually showed signs of improving .", "label": "", "metadata": {}, "score": "80.10397"}
{"text": "In these patients the development of liver cirrhosis is improbable .INTRODU\u00c7\u00c3O : Aproximadamente , 30 % dos portadores de hepatite cr\u00f4nica C apresentam n\u00edveis de aminotransferases persistentemente normais ( APNL ) .", "label": "", "metadata": {}, "score": "80.19095"}
{"text": "The patient then was initiated on traditional HCV treatment with pegylated interferon ( Pegasys , Peginterferon , PEG - Intron ) and ribavirin ( Copegus , Rebetol ) treatment . 1", "label": "", "metadata": {}, "score": "80.28311"}
{"text": "--Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C : A trial in prior monotherapy or combination therapy nonresponders and in combination therapy relapsers : Final Results .", "label": "", "metadata": {}, "score": "80.39849"}
{"text": "Background HIV therapy contained atazanavir ( ATV ) , ritonavir - boosted atazanavir ( ATV / r ) , efavirenz ( EFV ) , raltegravir ( RAL ) , tenofovir ( TDF ) , emtricitabine ( FTC ) or lamivudine ( 3TC ) .", "label": "", "metadata": {}, "score": "80.429695"}
{"text": "Counsel any patient with an FIB-4 index of more than 3.25 to reduce alcohol consumption or avoid alcohol altogether .This article was provided by TheBodyPRO.com .", "label": "", "metadata": {}, "score": "80.43075"}
{"text": "If they ca n't stop , they should follow safe injection practices ( always use a sterile syringe ; do not share drug solution , syringes , or drug preparation equipment ) .", "label": "", "metadata": {}, "score": "80.497345"}
{"text": "In fact , there are parallels with HIV .Before \" SMART \" it was thought that the toxicities of HIV therapy were driving many of the cardiovascular side effects in patients infected only with HIV .", "label": "", "metadata": {}, "score": "80.49757"}
{"text": "Figure 1 .Treatments for chronic hepatitis C in the present and future .PegIFN , peginterferon ; RBV , ribavirin .Standard of care ( SOC ) treatment for HCV infection .", "label": "", "metadata": {}, "score": "80.54816"}
{"text": "However , there is currently no evidence to support that explanation .Where we should leave this idea for now is that while it seems attractive to administer higher doses of ribavirin in the early weeks of hepatitis C treatment to improve rapid virologic response rates , the practice should still be considered experimental .", "label": "", "metadata": {}, "score": "80.60721"}
{"text": "This study was conducted at a single center with a single psychiatrist who was responsible for all treatment decisions .There was minimal need for dose reduction , the patients were very compliant with therapy , and there was close follow - up of the patients .", "label": "", "metadata": {}, "score": "80.65668"}
{"text": "This compound can stop HBV replication , and it was approved last September ( 2002 ) by the US FDA for the treatment of HBV .", "label": "", "metadata": {}, "score": "80.705215"}
{"text": "[Links ] .Rosenthal E , Poiree M , Pradier C , Perronne C , Salmon - Ceron D , Geffray L , et al .", "label": "", "metadata": {}, "score": "80.80968"}
{"text": "[Links ] .Palella Jr FJ , Delaney KM , Moorman AC , Loveless MO , Fuhrer J , Satten GA , et al .", "label": "", "metadata": {}, "score": "80.84552"}
{"text": "Division of Gastroenterology and Hepatology , Ospedale Maggiore Policlinico , Universit\u00e0 degli Studi di Milano , Milan 20100 , Italy .INGM , Istituto Nazionale Genetica Molecolare Milano , Milan 20100 , Italy .", "label": "", "metadata": {}, "score": "81.29265"}
{"text": "Direct Acting Antivirals ( DAA ) in HIV / HCV co - infection .Resolution of the three - dimensional structures of several HCV proteins , together with the development of replicative cell culture systems , has led to the identification of a number of potential targets for DAAs [ 20 ] .", "label": "", "metadata": {}, "score": "81.315094"}
{"text": "[ Google Scholar ] .Noureddin , M. ; Wright , E.C. ; Alter , H.J. ; Clark , S. ; Thomas , E. ; Chen , R. ; Zhao , X. ; Conry - Cantilena , C. ; Kleiner , D.E. ; Liang , T.J. ; et al .", "label": "", "metadata": {}, "score": "81.44038"}
{"text": "When used for 48 weeks , ADV 's safety profile is similar to placebo .The objective of this study was to compare the efficacy of ADV vs. placebo for the treatment of chronic hepatitis B virus infection in patients who are hepatitis E antigen positive .", "label": "", "metadata": {}, "score": "81.497665"}
{"text": "Faldaprevir ( BI 201335 ) is an inhibitor of HCV NS3/4A protease and is undergoing phase III clinical trials [ 52 , 53 ] .HCV NS5A and NS5B inhibitors .", "label": "", "metadata": {}, "score": "81.52456"}
{"text": "Triglycerides were independent predictors of steatosis in either of the HCV - groups .Dietary interventions and lifestyle changes should be proposed to prevent metabolic risk factors .", "label": "", "metadata": {}, "score": "81.75452"}
{"text": "Some DAAs are potent inhibitors independently of HCV genotypes [ 56 , 64 - 66 ] .The all - oral combination of daclatasvir plus sofosbuvir , with or without ribavirin , leads to higher SVR rates in treatment - naive patients chronically infected with HCV genotypes 1 , 2 and 3 [ 67 ] .", "label": "", "metadata": {}, "score": "81.83212"}
{"text": "Neither the BDI nor the CESD were able to predict the need for antidepressants .It appears that there were large variations in individual scores between participants , which may be the reason why these scales failed to predict patients ' need for treatment .", "label": "", "metadata": {}, "score": "81.91014"}
{"text": "The authors concluded that fat in the liver ( steatosis ) should be evaluated in prospective trials as a predictor of an early viral response .", "label": "", "metadata": {}, "score": "82.03752"}
{"text": "This study is important because it attempts to investigate the reasons for low platelets in patients who are treated with PEG IFN - alfa and RBV .", "label": "", "metadata": {}, "score": "82.08283"}
{"text": "Keywords .HIV Hepatitis C Direct acting antivirals Interferon Ribavirin .Introduction .The introduction of highly active antiretroviral therapy ( HAART ) in 1996 and the resultant sustained control of HIV replication and consequent immune reconstitution , has decreased HIV associated morbidity and mortality dramatically .", "label": "", "metadata": {}, "score": "82.256966"}
{"text": "Please note : Knowledge about HIV changes rapidly .Note the date of this summary 's publication , and before treating patients or employing any therapies described in these materials , verify all information independently .", "label": "", "metadata": {}, "score": "82.27818"}
{"text": "Nat .Genet 2009 , 41 , 1100 - 1104 .[ Google Scholar ] .Tanaka , Y. ; Nishida , N. ; Sugiyama , M. ; Kurosaki , M. ; Matsuura , K. ; Sakamoto , N. ; Nakagawa , M. ; Korenaga , M. ; Hino , K. ; Hige , S. ; et al .", "label": "", "metadata": {}, "score": "82.75394"}
{"text": "New standard of care treatment with telaprevir for chronic hepatitis C patients .Table 3 .New standard of care treatment with boceprevir for chronic hepatitis C patients .", "label": "", "metadata": {}, "score": "82.77026"}
{"text": "They include first - generation , second - wave and second - generation NS3 - 4A protease inhibitors , NS5B polymerase inhibitors , inhibitors of non - structural protein 5A and host - targeted agents , such as cyclophilin A inhibitors and microRNA-122 antagonists .", "label": "", "metadata": {}, "score": "82.8425"}
{"text": "PubMed View Article .Ann Intern Med 2013 , 159 : 86 - 96 .PubMed .Lancet Infect Dis 2013 , 13 : 597 - 605 .", "label": "", "metadata": {}, "score": "82.91434"}
{"text": "T1218 .Effect of therapy with pegylated interferon - alfa on platelet activation and apoptosis in patients with chronic hepatitis C. Low platelet counts are a frequent reason for medication discontinuation in HCV - infected patients who are treated with pegylated interferon .", "label": "", "metadata": {}, "score": "82.95429"}
{"text": "As for the polymerase drugs , they too have been plagued by toxicities ; many have been pulled from development in very early stages for this reason .", "label": "", "metadata": {}, "score": "83.05695"}
{"text": "Lancet 2000 ; 356:1800 - 1805 .[Links ] .Sulkowski MS , Moore RD , Mehta SH , Chaisson RE , Thomas DL .", "label": "", "metadata": {}, "score": "83.1638"}
{"text": "They will likely be tested individually and administered in addition to peginterferon and ribavirin and will not serve as a replacement for them .We may not see a combination of virus - specific ( i.e. , against specific viral functions ) drugs for many years .", "label": "", "metadata": {}, "score": "83.180405"}
{"text": "Methadone levels increased 10 - 15 % between baseline and Week 4 .Therefore , methadone appears to be safe to administer at the same time with PEG - IFN and RBV .", "label": "", "metadata": {}, "score": "83.255424"}
{"text": "Faldaprevir can be combined with ritonavir boosted darunavir but the dose needs to be reduced to 120 mg once a day .So far , first results from interaction studies with sofosbuvir , which is not metabolized by the cytochrome p450 pathway , indicate that this compound can be combined with darunavir / r , atazanavir / r or efavirenz [ 27 ] , thereby apparently offering more HIV treatment choices along with HCV therapy .", "label": "", "metadata": {}, "score": "83.353"}
{"text": "Undetectable virus at the end of treatment is called the end of treatment response ( ETR ) .However , therapy is deemed successful only if virus remains undetectable 6 months after treatment ends .", "label": "", "metadata": {}, "score": "83.406845"}
{"text": "Read the overview fact sheet in this series on drug users and viral hepatitis -- \" Viral Hepatitis and Injection Drug Users .\" It provides basic information , links to the other fact sheets in this series , and links to other useful information ( both print and Internet ) .", "label": "", "metadata": {}, "score": "83.47385"}
{"text": "Commentary : Overall , these two well - designed and well - executed studies have demonstrated that adefovir appears to be a superior therapy to lamivudine for the treatment of hepatitis B virus infection .", "label": "", "metadata": {}, "score": "83.53826"}
{"text": "PLoS One 2012 , 7 .[ Google Scholar ] [ CrossRef ] .Bochud , P.Y. ; Bibert , S. ; Kutalik , Z. ; Patin , E. ; Guergnon , J. ; Nalpas , B. ; Goossens , N. ; Kuske , L. ; M\u00fcllhaupt , B. ; Gerlach , T. ; et al .", "label": "", "metadata": {}, "score": "83.60698"}
{"text": "This was quite a sobering finding ; many of us had hoped there would be benefits from continuing the interferon , both from a histological standpoint and in terms of clinical outcome .", "label": "", "metadata": {}, "score": "83.94567"}
{"text": "Interferon and interferon plus ribavirin in hepatocellular carcinoma prevention .A prospective study on patients with HCV related cirrhosis .All cells in the body are required to divide in order to keep growing and to reproduce themselves .", "label": "", "metadata": {}, "score": "83.95566"}
{"text": "Of note , patients with constitutional neutropenia do not usually have reduced numbers of neutrophils when they are treated with interferon .Aggressive psychiatric intervention based on clinical suspicion , not standardized depression scores , increases adherence to pegylated interferon and ribavirin therapy for hepatitis C. Only 70 % of HCV - infected patients are able to tolerate the full - dose of PEG IFN / RBV for the recommended duration .", "label": "", "metadata": {}, "score": "84.46171"}
{"text": "The custom has been to treat patients who become neutropenic either with a reduction in the dose of interferon or to add another medication ( granulocyte colony stimulating factor - GCSF ) to increase the neutrophil count .", "label": "", "metadata": {}, "score": "84.51535"}
{"text": "Table 1 summarizes the corresponding drug interactions .Due to drug - drug interactions , boceprevir can only be currently safely combined with raltegravir , rilpivirine or etravirine in combination with tenofovir or abacavir and FTC or 3TC .", "label": "", "metadata": {}, "score": "84.59018"}
{"text": "ALT : 60 % of the patients in the ADV group had normalization of ALT , 40 % of the patients in the LAM / ADV group had normalization of ALT , and 5 % of the patients in the LAM group had normalization of ALT .", "label": "", "metadata": {}, "score": "84.77034"}
{"text": "JAMA 2002 ; 288:199 - 206 .[Links ] .Brau N , Bini EJ , Shahidi A , Aytaman A , Xiao P , Stancic S , et al .", "label": "", "metadata": {}, "score": "85.16176"}
{"text": "In the mid-1990s , RBV when added to IFN alfa , was noted to have increased antiviral activity when compared with IFN monotherapy .The current standard of care is pegylated interferon alfa in combination with RBV .", "label": "", "metadata": {}, "score": "85.162605"}
{"text": "Management of acute HCV is outside the scope of this article .Pegylated interferon and ribavirn therapy in HIV / HCV co - infection .Until recently , dual therapy with pegIFN and RBV has been the gold standard for HCV therapy in HIV co - infected individuals .", "label": "", "metadata": {}, "score": "85.28693"}
{"text": "Methadone may suppress IFN - alfa mediated antiviral activity .The objective of this study was to evaluate methadone 's effect on IFN - alfa activity and the effect of IFN - alfa on methadone safety and tolerability .", "label": "", "metadata": {}, "score": "85.497574"}
{"text": "Although there have been some improvements over the years with pegylated interferon and ribavirin , sustained virological response rates in HIV - infected patients are still , at best , in the 40 % range , which is inadequate .", "label": "", "metadata": {}, "score": "85.5535"}
{"text": "Regarding ALT levels , both of groups showed similar demographic characteristics and alcohol consumption ( Table 1 ) .In addition , the immunological parameters related to HIV infection and genotype distribution were not different between two groups ( Table 2 ) .", "label": "", "metadata": {}, "score": "85.68649"}
{"text": "STARTVerso4 is an open - label , sponsor - blinded study in HCV / HIV co - infected patients who were HCV treatment - na\u00efve ( TN ) or relapsed after previous HCV therapy to assess the efficacy and safety of faldaprevir q.d .", "label": "", "metadata": {}, "score": "85.84388"}
{"text": "[Links ] .Prati D , Taioli E , Zanella A , Della Torre E , Butelli S , Del Vecchio E , et al .", "label": "", "metadata": {}, "score": "85.87425"}
{"text": "Commentary : This study demonstrates that adefovir can significantly improve virologic , biochemical , and histologic parameters in HBV patients who are positive for the E antigen positive .", "label": "", "metadata": {}, "score": "85.961395"}
{"text": "Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C : A trial in prior monotherapy or combination therapy nonresponders and in combination therapy relapsers : Final Results .", "label": "", "metadata": {}, "score": "86.148575"}
{"text": "Lancet 2003 ; 362:22 - 29 .[Links ] .Sanchez - Quijano A , Andreu J , Gavilan F , Luque F , Abad MA , Soto B , et al .", "label": "", "metadata": {}, "score": "86.15999"}
{"text": "52nd Interscience Conference on Antimicrobial Agents and Chemotherapy ( ICAAC 2012 ) .San Francisco 2012 .Abstract H1921a .Pre - publication history .Copyright .", "label": "", "metadata": {}, "score": "86.202126"}
{"text": "IFN - alfa decreases a cell 's ability to divide .Therefore , investigators have thought that IFN 's ability to decrease cell division might delay or prevent liver cancer ( hepatocellular carcinoma ) .", "label": "", "metadata": {}, "score": "86.38821"}
{"text": "Superior efficacies of simeprevir and peginterferon plus ribavirin were observed compared to those of peginterferon plus ribavirin alone in treatment - naive [ 49 ] and previously treated patients ( Table 4 ) [ 50 ] .", "label": "", "metadata": {}, "score": "86.533775"}
{"text": "Serum HCV - RNA was quantified by Versant HCV - RNA 3.0 assay ( bDNA 3.0 ; Bayer Corporation , Emeryville , CA , USA ) , with a sensitive limit of 615 IU / mL and a dynamic range from 615 to 7,700,000 IU / mL. IL28B Genotyping .", "label": "", "metadata": {}, "score": "86.91403"}
{"text": "Competing interests .Dr. Tatsuo Kanda reports receiving lecture fees from Chugai Pharmaceutical , MSD , Ajinomoto , GlaxoSmithKlein and Mitsubishi Tanabe Pharma , and Prof. Osamu Yokosuka received grant support from Chugai Pharmaceutical , Bayer , MSD , Daiichi - Sankyo , and Mitsubishi Tanabe Pharma .", "label": "", "metadata": {}, "score": "86.9792"}
{"text": "Simeprevir ( TMC435 ) is an investigational HCV NS3/4A protease inhibitor administered orally once daily , and it is currently in phase III clinical development [ 48 ] .", "label": "", "metadata": {}, "score": "87.05162"}
{"text": "Knowledge Center .Read our more detailed articles about specific areas of medicine , conditions , nutrition and forms of treatment .", "label": "", "metadata": {}, "score": "87.354034"}
{"text": "Patients who failed to respond to a prior course of pegylated interferon and ribavirin were treated with one of two regimens of pegylated interferon and ribavirin .", "label": "", "metadata": {}, "score": "87.50831"}
{"text": "Reassuringly , no difference was seen in any clinical outcome between these two agents .Similar findings , although on a much smaller scale , were also described in a poster presented by Ana Moreno and colleagues .", "label": "", "metadata": {}, "score": "87.75518"}
{"text": "The goal of this study was to evaluate the effect of milk thistle on serum ALT levels and on patients ' quality of life .17 patients enrolled in double blind , placebo controlled study .", "label": "", "metadata": {}, "score": "87.95607"}
{"text": "T helper 1 ( Th1 ) responses are usually associated with defense against viral infections and are usually measured assessing interferon gamma secretion .T helper 2 ( Th2 ) responses are usually associated with defense against other types of infections and are usually measured by interleukin 4 or 10 secretion .", "label": "", "metadata": {}, "score": "88.3528"}
{"text": "Commentary : This is an important study because it shows that all patients who failed to respond to a prior course of interferon or interferon and ribavirin should be retreated with pegylated interferon and ribavirin .", "label": "", "metadata": {}, "score": "88.38023"}
{"text": "Publisher conditions are provided by RoMEO .Differing provisions from the publisher 's actual policy or licence agreement may be applicable .Hepatitis C ( HCV ) coinfection has become an increasingly important topic as morbidity and mortality from liver disease appear to be increasing among HIV - infected patients despite their living longer and doing better from an HIV standpoint .", "label": "", "metadata": {}, "score": "88.52233"}
{"text": "In summary , then , it appears that we will not see approval of any of these products until perhaps 2011 , when telaprevir may get its run through the U.S. Food and Drug Administration gauntlet .", "label": "", "metadata": {}, "score": "88.7839"}
{"text": "Hyperbilirubinemia ( a known side effect of simeprevir ) was noted in 5 % of study subjects .However , only 4 % of patients discontinued simeprevir because of adverse events .", "label": "", "metadata": {}, "score": "88.85101"}
{"text": "However , the response to lamivudine may not last as long as with alpha interferon .In addition , stopping lamivudine is often followed by relapse , and continuing lamivudine indefinitely often leads to antiviral resistance . have a liver biopsy that shows moderate disease activity and fibrosis .", "label": "", "metadata": {}, "score": "88.93711"}
{"text": "EuroSIDA Study Group .Lancet 1998 ; 352:1725 - 1730 .[Links ] .Mocroft A , Ledergerber B , Katlama C , Kirk O , Reiss P , d'Arminio Monforte A , et al .", "label": "", "metadata": {}, "score": "88.95249"}
{"text": "JKR and SB have both written this review and both authors read and approved the final manuscript .Authors ' Affiliations .Department of Medicine I , University Hospital Bonn .", "label": "", "metadata": {}, "score": "89.12605"}
{"text": "Concomitant antiretroviral therapy ( ART ) also had no impact on early virological response .Adverse events were frequent ( 99 % of patients developed an AE ) but were mostly related to pegIFN side effects .", "label": "", "metadata": {}, "score": "89.59802"}
{"text": "Boston , Massachusetts : Program and abstracts of 63rd Annual Meeting of the American Association for the Study of Liver Diseases ; 2012 .Boston , Massachusetts : Program and abstracts of 63rd Annual Meeting of the American Association for the Study of Liver Diseases ; 2012 .", "label": "", "metadata": {}, "score": "89.66931"}
{"text": "Histological Assessment .Liver biopsies ( LBs ) were performed with a 16-gauge Tru - cut needle ( Uro - Cut 16 G , TSK , Tokyo , Japan ) and read by two independent pathologists ( Roberta D'Ambrosio , Guido Ronchi ) who were unaware of the patient 's IL28B genotype .", "label": "", "metadata": {}, "score": "90.1519"}
{"text": "In terms of how to treat patients with HBV who are currently on lamivudine and who have the YMDD mutation , the question has recently arisen regarding what should be done with the lamivudine .", "label": "", "metadata": {}, "score": "90.35918"}
{"text": "To answer this question , Dr. Thomas referred his audience to an important study : ACTG 5178 , also called the SLAM - C study .", "label": "", "metadata": {}, "score": "90.37102"}
{"text": "Although currently a highly popular choice are regimens based on tenofovir / emtricitabine ( TDF / FTC , Truvada ) , that 's still a restrictive formulary for use in our patients .", "label": "", "metadata": {}, "score": "90.54703"}
{"text": "This article is published under license to BioMed Central Ltd. all Addendum Article Book Review Case Report Comment Commentary Communication Concept Paper Conference Report Correction Creative Data Descriptor Discussion Editorial Erratum Essay Interesting Images Letter New Book Received Obituary Opinion Project Report Reply Retraction Review Short Note Technical Note .", "label": "", "metadata": {}, "score": "90.94931"}
{"text": "Dosing was based upon body surface area ( BSA ) .Blood samples were obtained at weeks 1 , 4 , 8 , 12 , 24 , 40 , and 48 during therapy and at 1 , 24 , and 48 post - treatment .", "label": "", "metadata": {}, "score": "92.12873"}
{"text": "Alpha interferon stimulates the body 's immune system to fight the infection , but it is expensive , must be administered by injection , and has many side effects .", "label": "", "metadata": {}, "score": "92.24527"}
{"text": "In the present clinical trials , in their stead , several second - generation DAAs are being investigated .Most of them are being viewed with high expectations , but they also require the combination with peginterferon plus ribavirin .", "label": "", "metadata": {}, "score": "92.3503"}
{"text": "[Links ] .Bani - Sadr F , Barange K , Daoud F , Jacomet C , Bicart - See A , Rosenthal E , et al .", "label": "", "metadata": {}, "score": "93.67911"}
{"text": "Liver Biopsies Reading : Roberta D'Ambrosio and Guido Ronchi .IL28B Genotyping ; Raffaele De Francesco , Enrico Galmozzi and Cristina Cheroni .Analysis and Interpretation of data : Roberta D'Ambrosio , Alessio Aghemo , Pietro Lampertico .", "label": "", "metadata": {}, "score": "93.82032"}
{"text": "Pacientes com pelo menos 3 determina\u00e7\u00f5es normais da ALT nos \u00faltimos 6 meses antes da bi\u00f3psia hep\u00e1tica foram considerados como tendo APNL .Todos foram submetidos a bi\u00f3psia hep\u00e1tica que foi classificada de acordo com a escala METAVIR .", "label": "", "metadata": {}, "score": "94.091705"}
{"text": "Several studies have demonstrated that combination therapy with pegylated interferon and ribavirin is superior to interferon monotherapy or combination therapy with standard interferon and ribavirin .", "label": "", "metadata": {}, "score": "94.41644"}
{"text": "[Links ] .Benhamou Y , Bochet M , Di Martino V , Charlotte F , Azria F , Coutellier A , et al .", "label": "", "metadata": {}, "score": "94.7534"}
{"text": "Duke Clinical Research Institute , Duke University , Durham , NC 27715 , USA .Kirby Institute for Infection and Immunity in Society , University of South Wales , Kensington 2033 , Australia .", "label": "", "metadata": {}, "score": "94.862175"}
{"text": "Both the alpha and pegylated interferons are given by injection ; ribavirin is taken as pills .All of these drug regimens have many side effects , some of which can be serious .", "label": "", "metadata": {}, "score": "95.68385"}
{"text": "The Statistical Package for the Social Sciences ( SPSS ) software package version 10 ( SPSS Inc. , Chicago , IL ) was used .Ethical considerations .", "label": "", "metadata": {}, "score": "95.878784"}
{"text": "All study contributors have been listed as authors .Conflicts of Interest .The authors declare no conflict of interest .Author Contributions Study Conception and Design : Roberta D'Ambrosio , Alessio Aghemo , Massimo Colombo .", "label": "", "metadata": {}, "score": "96.228165"}
{"text": "Laboratory Assessment .Baseline anthropometric measurements , including the height and weight for calculating the body mass index , were recorded .An overnight ( 12 h ) fasting blood sample was taken for routine analysis ( e.g. , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , gamma - glutamyl transpeptidase ( \u03b3GT ) , cholesterol , triglycerides , glucose and insulin .", "label": "", "metadata": {}, "score": "96.51567"}
{"text": "Quality of life was measured using a standardized , validated instrument ( the state trait anxiety inventory ( STAIS ) , which tests several different physical , mental , and psychological traits associated with quality of life .", "label": "", "metadata": {}, "score": "97.18831"}
{"text": "Competing interests .In the last five years , J\u00fcrgen Rockstroh has received honoraria for speaking at educational events or for consulting for Abbott , Abbvie , Astella , Bionor , BMS , Boehringer Ingelheim , Gilead , Janssen , Merck , Novartis , Pfizer , Vertex and ViiV. In the last five years , Sanjay Bhagani has received honoraria for speaking at educational meetings , attending advisory meetings or travel support for attending conferences from Abbvie , BMS , Boehringer Ingelheim , Gilead , Janssen , MSD and Roche .", "label": "", "metadata": {}, "score": "97.22481"}
{"text": "The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease .It is not a substitute for professional care .", "label": "", "metadata": {}, "score": "98.05707"}
{"text": "Statistical Analysis .Statistical analyses were conducted using the Mann - Whitney U test or the Student 's t -test for continuous variables and the \u03c7 2 or Fisher exact probability test for categorical data .", "label": "", "metadata": {}, "score": "98.466324"}
{"text": "Daclatasvir is a potent NS5A replication complex inhibitor and increases the antiviral potency of peginterferon and ribavirin [ 55 ] ( Tables 4 ) .Table 5 .", "label": "", "metadata": {}, "score": "99.59216"}
{"text": "There are several questionnaires that have been developed that are used to test patients for depression .The aim of this study was to test the ability of two measures of depression , the Beck Depression Index ( BDI ) and the Center for Epidemiologic Study ( CES - D ) to test whether changes in these two measurements could predict depression .", "label": "", "metadata": {}, "score": "100.2154"}
{"text": "Drafting of the Manuscript : Roberta D'Ambrosio and Alessio Aghemo .Critical Revision : Roberta D'Ambrosio , Alessio Aghemo , Maria Grazia Rumi , Pietro Lampertico , Massimo Colombo .", "label": "", "metadata": {}, "score": "100.27733"}
{"text": "Received : 25 February 2014 ; in revised form : 26 March 2014 / Accepted : 28 March 2014 / Published : 25 April 2014 .", "label": "", "metadata": {}, "score": "105.999275"}
{"text": "Quantitative variables were expressed as average \u00b1 standard deviation ( SD ) and were compared using the Student 's t -test .Percentages were compared using c 2 test and Fisher 's exact test when appropriate .", "label": "", "metadata": {}, "score": "106.09189"}
{"text": "In healthy patients the normal range for serum ALT level was set in the 1955 by Karmen 32 and has changed little since then .Current upper limit of normality ( ULN ) were set , on average , from 30 to 50U / L. This was recently challenged by a research group , who claimed that the true normal values are significantly lower .", "label": "", "metadata": {}, "score": "106.26114"}
{"text": "As liver disease progresses and the liver becomes more fibrotic , the blood in the portal system encounters much more resistance .The increase in pressure in the portal system causes the spleen to enlarge .", "label": "", "metadata": {}, "score": "106.283554"}
{"text": "F\u00e1bio Heleno de Lima Pace I ; Lincoln Eduardo Vieira de Castro Ferreira II ; Antonio Eduardo Benedito Silva III ; Maria Lucia Gomes Ferraz III .", "label": "", "metadata": {}, "score": "108.55702"}
{"text": "Acknowledgements .The authors would like to thank Drs .Christoph Boesecke and Jan - Christian Wasmuth for the feedback each provided on this manuscript and/or the concepts therein .", "label": "", "metadata": {}, "score": "109.31467"}
{"text": "We seem therefore to be caught between Scylla and Charybdis , deferring therapy when there is little fibrosis due to the toxicity of treatment only to have the treatment success diminished or contraindicated altogether in patients who really need it .", "label": "", "metadata": {}, "score": "111.658066"}
{"text": "Web . 9 Feb. 2016 .Contact our news editors .For any corrections of factual information , or to contact our editorial team , please see our contact page .", "label": "", "metadata": {}, "score": "115.597176"}
{"text": "For a complete listing of our most recent conference coverage , click here .TheBodyPRO.com is a service of Remedy Health Media , LLC , 750 3rd Avenue , 6th Floor , New York , NY 10017 .", "label": "", "metadata": {}, "score": "119.69026"}
{"text": "Published by Elsevier Inc.All rights reserved .Data provided are for informational purposes only .Although carefully collected , accuracy can not be guaranteed .", "label": "", "metadata": {}, "score": "122.728065"}
{"text": "General Disclaimer : TheBodyPRO.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services .The information provided through TheBodyPRO.com should not be used for diagnosing or treating a health problem or a disease .", "label": "", "metadata": {}, "score": "126.958336"}
{"text": "For more information , please read our terms of use .Copyright Medical News Today : Excluding email / sharing services explicitly offered on this website , material published on Medical News Today may not be reproduced , or distributed without the prior written permission of Medilexicon International Ltd.", "label": "", "metadata": {}, "score": "129.76251"}
